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Abstract
Ischemia–reperfusion injury (IRI) is one of the biggest challenges for cardiovascular researchers given the huge death 
toll caused by myocardial ischemic disease. Cardioprotective conditioning strategies, namely pre- and post-conditioning 
maneuvers, represent the most important strategies for stimulating pro-survival pathways essential to preserve cardiac health. 
Conditioning maneuvers have proved to be fundamental for the knowledge of the molecular basis of both IRI and cardiopro-
tection. Among this evidence, the importance of signal transducer and activator of transcription 3 (STAT3) emerged. STAT3 
is not only a transcription factor but also exhibits non-genomic pro-survival functions preserving mitochondrial function 
from IRI. Indeed, STAT3 is emerging as an influencer of mitochondrial function to explain the cardioprotection phenomena. 
Studying cardioprotection, STAT3 proved to be crucial as an element of the survivor activating factor enhancement (SAFE) 
pathway, which converges on mitochondria and influences their function by cross-talking with other cardioprotective path-
ways. Clearly there are still some functional properties of STAT3 to be discovered. Therefore, in this review, we highlight 
the evidence that places STAT3 as a promoter of the metabolic network. In particular, we focus on the possible interactions 
of STAT3 with processes aimed at maintaining mitochondrial functions, including the regulation of the electron transport 
chain, the production of reactive oxygen species, the homeostasis of  Ca2+ and the inhibition of opening of mitochondrial 
permeability transition pore. Then we consider the role of STAT3 and the parallels between STA3/STAT5 in cardioprotec-
tion by conditioning, giving emphasis to the human heart and confounders.
Keywords Ca2+ regulation · Ischemia reperfusion injury · Mitochondrial permeability transition pore · Reactive oxygen 
species · RISK pathway · SAFE pathway · STAT3 · STAT5
Introduction
Global health is constantly threatened by cardiovascular 
diseases (CVDs) and every year 31% of worldwide deaths 
are caused by fatal CVDs. According to the World Health 
Organization, CVDs caused 17.9 million deaths in 2016. 
Among these, 85% are attributed to ischemic heart disease 
or stroke [186].
Over the past twenty to thirty years, mortality from 
ischemic heart disease has significantly decreased. However, 
currently available therapies improve symptoms and slow 
pathological heart remodeling but fail to further reduce CVD 
mortality [178]. A complete understanding of the molecu-
lar targets and mechanisms underlying heart disease is cer-
tainly the key to developing new and effective therapeutic 
strategies.
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Coronary reperfusion is currently the “gold standard” for 
saving the lives of patients with acute myocardial infarction 
(MI). Reperfusion is mandatory to avoid fatal damage to 
the ischemic myocardium. However, the reperfusion itself 
contributes to exacerbating the damage and the extent of the 
infarct size (IS). In this regard, cardiovascular research over 
the years has investigated how to limit ischemia–reperfusion 
injury (IRI), leading to the development of cardioprotective 
maneuvers, which allowed researchers to analyze and under-
stand the molecular aspects of IRI [77].
Already in 1972 Braunwald and collaborators suggested 
that the infarct area was not only a function of the duration 
of ischemia, the area at risk and collateral flow, but could 
also be reduced with cardioprotective interventions [144]. 
However, only in 1986 Murry et al. [153] demonstrated in 
an animal model that a few minutes of coronary occlusion 
interspersed with a few minutes of reperfusion reduced the 
area of myocardial infarction caused by a subsequent period 
of prolonged lethal ischemia/reperfusion (IR). This was the 
discovery of ischemic preconditioning (IPreC) as a pow-
erful endogenous cardioprotective phenomenon. However, 
only 4 years later another laboratory confirmed this original 
observation [130]. Since that time, the IS-limiting effects of 
IPreC have been demonstrated in all species tested, includ-
ing humans and have also been shown to be effective in 
the multicenter network of experimental research centers 
that made up the Consortium for preclinicAl assESsment 
of cARdioprotective therapies (CAESAR) [94]. It was then 
demonstrated that the preconditioned state resulted from 
protective signal transduction [226]. It was discovered that 
a short coronary occlusion releases ligands (e.g., adenosine, 
bradykinin, opioids, platelet activating factor and/or sphin-
gosine) which acting on their receptors trigger protective 
cascades that converge on protein kinase C (PKC) [138, 166] 
and on mitochondria [137]. The production of reactive oxy-
gen species (ROS) with a trigger role for cardioprotection 
also plays an important role in this mechanism [212]. The 
importance of mitochondria in these phenomena is certain, 
as much of the cell death in the heart is due to the formation 
of mitochondrial permeability transition pores (mPTPs) in 
the first minutes of reperfusion, which is prevented by con-
ditioning procedures [75, 78].
The cardioprotective pathways are not yet fully under-
stood, but in the early 2000s, Yellon's group [72, 182] pro-
posed the reperfusion injury salvage kinase (RISK) pathway, 
which includes pro-survival kinases that must be activated 
at the time of reperfusion to protect against IRI (Fig. 1). 
Then, studies have shown that it is possible to protect the 
heart with short intermittent phases of ischemia applied at 
the beginning of reperfusion, ischemic postconditioning 
(IPostC) [215, 248], as well as by ischemia in tissues and 
organs remote to the heart, remote ischemic conditioning 
(RIC) [171]. Indeed, these conditioning maneuvers trigger 
via multiple mechanisms various cardioprotective pathways 
besides the RISK, including the NO/PKG (nitric oxide/
cyclic guanosine monophosphate (cGMP)-dependent pro-
tein kinase G; Fig. 1), and the so-called survivor activating 
factor enhancement (SAFE) pathways, which can cross-talk 
(Figs. 1 and 2) [71, 197, 209]. The SAFE pathway was pro-
posed in 2009 by Lecour et al. [113], it considers a central 
role for the signal transducer and activator of transcription 
3 (STAT3) and will be described in more detail throughout 
this review article.
The importance of the RISK and/or SAFE pathway has 
been demonstrated in all forms of ischemic conditioning 
(IPreC, IPostC and RIC) as well as in that obtained with 
substances administered before or after infarcting ischemia 
(pharmacological conditioning) [69, 238]. The mechanisms 
induced by pharmacological conditioning are similar to 
IPreC and IPostC, with the difference that pharmacologi-
cal conditioning could be applied in a less invasive way. 
Indeed, in animal and clinical studies, many substances have 
shown to induce protection against myocardial IR, includ-
ing volatile anesthetics, opioids, some anti-diabetic drugs, 
statins but also endogenous substances and hormones, such 
as adenosine, leptin, insulin and ghrelin [71, 114, 115, 168]. 
In addition, hypothermic conditioning by mild hypothermia 
(32–35 °C) has been described in the contest of myocardial 
protection and STAT3 in animal and in clinical studies [88, 
161, 163]. It is now clear that targeting intra-cardiomyocytes 
pathways together a multitarget approach is necessary for 
a successful cardioprotective strategy (EU-CARDIOPRO-
TECTION COST Action CA16225) [39].
Of note, in preconditioning obtained with interventions/
agents, the cardioprotection occurs in two phases, in which 
STAT3 has been seen to play a pivotal role, as member of 
the SAFE pathway. The first phase is called classical or early 
preconditioning and lasts 2–3 h. The second phase is called 
second window of protection (SWOP) or delayed or late pre-
conditioning. It starts about 12 h after the IPreC maneuvers 
and lasts 48–72 h [73].
Although, STAT3 is involved as a transcription factor 
inducing the upregulation of antioxidant, antiapoptotic 
and pro-angiogenic genes in SWOP [22, 251], it has been 
recently observed in cardiac mitochondria in the mainte-
nance of electron transport chain (ETC) activity and in the 
prevention of opening of mPTPs [225, 236]. In addition, the 
mitochondrial activity of STAT3 is emerging as an impor-
tant factor and may represent the needle of the balance in 
mechanisms that confer cardioprotection. Notwithstanding 
that some studies reported the role of STAT3 in cardiac con-
ditioning, others evidenced the important involvement of 
STAT5 for the translation of cardioprotection [e.g., 56, 80].
Therefore, in this review we first briefly describe the 
structure of STAT3 and the principal STAT3 post-transla-
tional modifications. Then we focus on the role of STAT3 
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within mitochondria highlighting the evidence that places 
STAT3 as a promoter of the metabolic network. In particu-
lar, we focus on the possible interactions of STAT3 with 
the ETC, the production of ROS, the  Ca2+ homeostasis, the 
mitochondria quality control and the inhibition of mPTPs 
opening. We also provide a critical evaluation of pathophysi-
ological roles of STAT3 and the parallels between STA3/
STAT5 in the context of cardiac IRI. Finally, we discuss 
the role of STAT3 in the cardioprotection by ischemic and 
pharmacological/hypothermic conditioning and the effects 
of common risk factors and confounders on STAT3-medi-
ated cardioprotection in cells, in animal models and in the 
human heart.
STAT3 overview
To begin, we briefly consider STAT3 structure, evolutionary 
conservation of stat genes, their regulation and the subcel-
lular STAT3 localization. For a more detailed description the 
readers are kindly redirected to recent reviews [10, 60, 223].
Structure of STAT3
STAT3 together with STAT 1-2-4, STAT5a-b, and STAT6 
are members of the STAT family. These proteins exhibit dif-
ferent functions while having an almost similar structure. 
This family of signal molecules appeared early in evolution 
and differentiated during the evolution of animal species. 
During animal development, the STAT signaling pathway 
regulates cell fate decisions. Comparative genomics dis-
played multiple duplications of the stat gene that occurred 
throughout the evolutionary history of metazoans. Many of 
these STAT duplications evolved into new genes through 
rapid sequence differentiation and the acquisition of new 
functions. It appears that the regulatory networks of stat 
genes, which include stat1, 4, 5 and stat6, appeared early 
in vertebrate evolution. Among the STAT genes, the gene 
encoding STAT3 is the only one that is essential for the early 
development of vertebrate embryos and results in embry-
onic lethality if it is completely deleted [207]. In mammals, 
the two stat5 genes likely arose from a duplication event in 
early Eutherian evolution, a period from about 310 to 130 
Fig. 1  Cardiac conditioning can be induced by brief periods of 
ischemia (red lines), that is ischemic preconditioning (IPreC), post-
conditioning (IPostC) and remote conditioning (RIC), as well as by 
hypothermic or pharmacological interventions. Pre-, Per- and Post-
conditioning are able to protect the heart vs IRI, by triggering three 
main transduction pathways, SAFE, RISK and NO/PKG pathways; 
these pathways can cross-talk and result in the activation of anti-
apoptotic stimuli and the preservation of mitochondrial function. Akt 
Protein kinase B, cGMP cyclic Guanosine Monophosphate, eNOS 
endothelial Nitric Oxide Synthase, ERK1/2 Extracellular Receptor 
Kinase ½, GSK3β Glycogen Synthase Kinase-3β, IPreC Ischemic 
PreConditioning, JAK Janus Kinase, MAPK Mitogen-Activated Pro-
tein Kinase, MEK MAPK/ERK Kinase, NO Nitric Oxide, PI3K Phos-
phatidylInositol-4,5-bisphosphate 3-Kinase, PKCε Protein Kinase C 
ε subtype, PKG Protein Kinase G, RAF serine/threonine kinase, RAS 
rat Sarcoma Virus, RISK Reperfusion Injury Salvage Kinase, SAFE 
Survivor Activating Factor Enhancement, STAT3 Signal Transducer 
and Activator of Transcription 3
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million years ago when the avian-mammal divergence and 
the separation of marsupials from other mammals occurred 
[60, 223]. These comparative analyzes indicate that genome-
wide duplications and gene duplications for unbalanced 
chromosomal crossings were probably the main mechanisms 
underlying the evolution of STATs [223]. The selective per-
sistence of the basic domains required for phospho-tyrosine 
signaling, as well as the Src homology-2 (SH2) domain 
and a site for protein tyrosine phosphorylation, suggest the 
importance of these modules in all multicellular organisms. 
It is, therefore, of particular interest that the different pro-
teins of the STAT family have acquired additional functions, 
apparently independent of phospho-tyrosine, without los-
ing their participation in the basic signaling mode [61, 121, 
225].
Members of the STAT family interact with janus kinase 
(JAK) proteins, including JAK1, JAK2, JAK3 and tyrosine 
kinase 2 (TYK2) [12]. For details on this interaction, the 
reader is redirected to a previous review [129].
The human STAT3 protein (89 kDa), encoded by the stat3 
gene, is constituted by 770 amino acids that are organized 
in 6 different domains [111] (Fig. 3). STAT3 contains an 
N-terminal oligomerization domain (OLG), whose role is 
still unclear; it does not seem to be involved in the formation 
of phosphorylated STAT3 homodimers nor in the interaction 
with DNA, but is suggested to play a role in non-canonical 
STAT3 signaling and in the formation of unphosphoryl-
ated STAT3 dimers [44]. Close to the OLG domain is the 
coiled-coil dimerization domain, which is involved in the 
interaction of STAT3 with regulators and other transcription 
Fig. 2  STAT3 canonical and non-canonical pathways. In SAFE 
pathway JAK/STAT3 can be activated upon activation of receptors 
including gp130, TNFR2, S1PR. Other molecules (not represented 
in figure) may activate SAFE pathway, including HDL, Melatonin, 
Erythropoietin, Insulin and Leptin. Upon phosphorylation at Y705 
and dimerization, STAT3 dimer travels to the nucleus, where it reg-
ulates gene transcription. The phosphorylation at S727 may allow 
STAT3 to interact with GRIM19 and TOM20 to enter the mitochon-
dria. STAT3 has been shown to interact with multiple mitochondrial 
proteins, such as MCU, promoting mitochondrial  Ca2+ entry, com-
plex I and II of the ETC, increasing ATP level and decreasing ROS 
production. STAT3 interacting with CypD prevents the opening of 
mPTPs. STAT3 has been detected also in the MAM fraction, where 
it is able to promote IPR3 degradation and prevent cytosolic  Ca2+ 
accumulation. Akt Protein kinase B, ATP adenosine triphosphate, Bcl-
xL B-cell lymphoma-extra large, COX2 Cytochrome c oxidase subu-
nit 2, CypD Cyclophilin D, Cyt C Cytochrome C, ER Endoplasmic 
Reticulum, ERK1/2 Extracellular Receptor Kinase ½, ETC Electron 
Transport Chain, gp130 glycoprotein 130, GRIM19 Gene associated 
with Retinoid Interferon-induced cell Mortality 19, HDL High Den-
sity Lipoprotein; IP3R, Inositol 1,4,5-trisphosphate Receptors, JAK 
Janus Kinase, MAM Mitochondrial-Associated ER Membrane, MCl-1 
Myeloid cell leukemia 1, MCU Mitochondrial Calcium Uniporter, 
mPTP mitochondrial Permeability Transition Pore, ROS Reactive 
oxygen species, S1P Sphingosine-1-Phosphate, S1PR Sphingosine-
1-Phosphate Receptors, SAFE Survivor Activating Factor Enhance-
ment, SERCA Sarco-Endoplasmic Reticulum Calcium ATPase, SK1 
Sphingosine Kinase 1, SOCS3 Suppressor of Cytokine Signaling 3; 
SOD2 Superoxide dismutase 2, STAT3 Signal Transducer and Acti-
vator of Transcription 3, TNFR2 Tumor Necrosis Factor Receptor 2; 
TOM20Translocase of the outer membrane 20, TRAF2 TNF-Recep-
tor-Associated-Factor 2, VDAC Voltage-Dependent Anion Channels, 
VEGF Vascular endothelial growth factor
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factors. STAT3 comprises also a DNA binding domain 
(DBD) that is able to interact with the interferon γ-activated 
sequence (GAS) in the promoter of specific genes; the inter-
action with the DNA is mediated by four loops of STAT3, 
three loops belong to the DNA binding domain and one to 
the linker domain [13]. The linker domain also cooperates 
with the SH2 domain in the recognition of YXXQ sites. The 
SH2 domains recognize phosphorylated tyrosine residues of 
activated STAT3, allowing the formation of STAT3 homodi-
mers that are essential in the canonical STAT3 signaling. 
The SH2 domains mediate the recognition of other phospho-
rylated tyrosine residues, for example on glycoprotein 130 
receptor (gp130) [222]. Although the SH2 domain is highly 
conserved in the STAT family, it was possible to design spe-
cific inhibitors of STAT3 targeting the SH2 domain, such as 
Stattic or S3I-201 [41].
At the C-terminus, the transcription activation domain 
(TAD) can be detected with two phosphorylation sites, 
Tyrosine 705 (Y705) and Serine 727 (S727). The STAT3 
phosphorylation at these two sites will be recognized by 
a specific pocket in the SH2 domain of the other STAT3 
monomer; therefore, TAD domain participates in the stabil-
ity of the homodimer and to activation of STAT3 signaling. 
For the recognition of Y705 and S727, the SH2 domain of 
STAT3 requires the presence of arginine, R609 that is highly 
conserved in all SH2 domains [184]. There are two main 
isoforms of STAT3 (α and β), which differ in the length of 
the C-terminus: the most abundant STAT3α comprises 770 
amino acids and the less frequent STAT3β, which lacks 48 
amino acids of the TAD, including the S727 phosphorylation 
site (Fig. 3) [184].
STAT3 canonical functions are primarily described 
as translocation from cytoplasm to the nucleus, where 
it acts as a transcription factor. However, STAT3 acts in 
non-canonical ways outside from the nucleus, by regulat-
ing the functions of mitochondria, endoplasmic reticulum 
(ER) and lysosomes. Yet, co-localization of cytoplasmic 
STAT3 with a microtubule-destabilizing protein stathmin 
favors microtubule polymerization and cell movement 
[158].
Effects of STAT3 on mitochondrial function are 
described below (see “Effects of STAT3 on mitochondrial 
function”). Here, we briefly describe the role in lysosomes 
and ER. STAT3 associates with lysosomes, spherical 
vesicles whose lumen's acidic pH (~ 4.5–5.0) is optimal 
for the enzymes involved in hydrolysis of different bio-
molecules. In lysosomes, STAT3 stimulates V-ATPase 
activity and contributes to the preservation of the acidic 
lysosomal lumen and the alkaline cytosol [135]. The ER 
is the principal  Ca2+ storage compartment and its close 
contact with mitochondria membrane determines mito-
chondrial  Ca2+ responses in many cell types [176]. STAT3 
phosphorylation at Y705 and S727 residues (see below 
“Phosphorylation at Y705 and S727”) are not required 
for either ER localization or Inositol 1,4,5-trisphosphate 
Receptor (IP3R) type 3 (IP3R3) interaction. However, the 
phosphorylation on S727 may play an important regula-
tory role, as murine embryonic fibroblast cells express-
ing a STAT3 mutant on S727 showed excess  Ca2+ release 
and apoptotic cell death after treatment with  H2O2 or the 
intracellular ROS generator menadione, which induce 
cell death by apoptosis. These effects were not observed 
in wild type cells. Furthermore, ER STAT3 acts by pro-
moting the proteasomal degradation of IP3R3, probably 
through the ubiquitin E3 ligase FBXL2 in mammalians [9, 
103]. These observations are consistent with the fact that 
some breast cancers show an inverse correlation between 
phospo-STAT3 and IP3R3 protein levels [9].
Fig. 3  Structural representation of STAT3 dimer bound to a DNA 
molecule (molecular graphic performed with UCSF Chimera) and 
schemes of STAT3α and STAT3β domains. Red asterisks represent 
Y705 and S727 phosphorylation sites. DNA Deoxyribonucleic acid, 
STAT3 Signal Transducer and Activator of Transcription 3, UCSF 
University of California, San Francisco
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Post‑translational modifications of STAT3: 
focus on the SAFE pathway
STAT3 post-translational regulations include phosphoryla-
tions and alternative post-translational modifications.
Apart from the phosphorylation of Y705 and/or S727 
residues, STAT3 is reported to undergo alternative post-
translational modifications, such as K685 acetylation, or 
C259 nitrosylation, and other modifications in non-canon-
ical pathways. Here, for space constraint, we choose to 
consider mainly Y705 and S727 phosphorylation, which 
are pivotal in the SAFE pathway. All post-translational 
modifications are described and summarized in Table 1; 
for further information about STAT3 post-translational 
modifications the reader is redirected to previous reviews 
[66, 251].
Phosphorylation at Y705 and S727
It seems that, while the Y705 phosphorylation of STAT3 
is necessary for homodimerization and translocation in the 
nucleus, S727 phosphorylation is necessary for its trans-
location into the mitochondria [78, 79, 225]. Data suggest 
that a dynamic balance exists between the phosphorylation 
of Y705 and S727, which is achieved through a possible 
inhibitory effect of phosphorylated S727 on phosphoryl-
ated Y705 [11, 39, 239]. Nevertheless, the results obtained 
are still discordant and the role of phosphorylation in car-
diovascular tissues is still not well defined.
Phosphorylated STAT3 belongs mainly to the JAK/
STAT signaling pathway that is a multifunctional pathway 
that regulates immunity, cell division, cell death and cell 
differentiation [173]. Different receptors can activate this 
pathway, including the Erythropoietin, Leptin and Angio-
tensin II receptors, as well as the Tumor Necrosis Factor 
Receptor 2 (TNFR2) and Gp130. The latter is a common 
receptor for the cytokines of the Interleukin 6 (IL-6) fam-
ily including IL-5, IL-6, IL-11, Oncostatin M, Leukemia 
Inhibitory Factor, and Cardiotrophin 1. Upon ligand bind-
ing, the receptor undergoes multimerization that brings 
JAK proteins associated with the receptor cytoplasmic tail 
close together, allowing trans-phosphorylation. The acti-
vated JAK proteins phosphorylate the YXXQ sites on the 
receptor's cytoplasmic domain. These sites are recognized 
by the SH2 domain of STAT3, which will be in turn phos-
phorylated by JAKs on Y705 of the TAD.
The phosphorylation of Y705 is the crucial event 
needed to induce the dimerization of STAT3. STAT3 
dimers move into the nucleus and regulate the transcription 
of different genes through the DBD. Y705 phosphorylation 
of STAT3 occurs as consequence of the stimulation by 
various cytokines, such as IL-6 and Interferon γ (IFNγ), 
as well as growth factors, such as Fibroblast Growth Fac-
tor and Epidermal Growth Factor (EGF) [249]. Therefore, 
the induction of these pathways stimulates the phospho-
rylation of Y705, which subsequently leads to dimeriza-
tion and translocation of the protein into the nucleus and 
constitutes the canonical pathway of STAT3 activation 
(Fig. 2).
It has been reported that mitogen-activated protein 
kinase (MAPK) family members including extracellular 
receptor kinase 1/2 (ERK1/2), c-Jun N-terminal kinase 
(JNK), and p38 can phosphorylate STAT3 at S727 [66]. 
Intriguingly, ERK1/2 is activated upon growth factors and 
cytokine stimulation and provides cardioprotection in IR 
settings via the RISK pathway activation [213]. Yet, JNK 
and p38 are known to be activated upon stress conditions 
and inflammatory cytokines, such as TNFα, which is also 
involved in SWOP [40] and SAFE (see below,  “STAT3 in 
the SAFE Pathway”). Interestingly, p38 is known to be a 
mediator of IRI, while JNK may have a dual effect, since 
evidence of JNK participating in myocardial damage [175] 
or in cardioprotection [185] have been reported.
Other serine/threonine kinases that are able to phos-
phorylate S727 are protein kinase C (PKCε and PKCδ 
isoforms), mammalian target of rapamycin (mTOR) and 
cyclin dependent kinase 5 (CDK5) [252]. Of note, the acti-
vation of PKCε before ischemia protects mitochondrial 
function and reduces apoptosis, mimicking IPreC, whereas 
it seems that the inhibition of PKCδ during reperfusion 
protects the heart from IR injury. Nevertheless, conflict-
ing studies have suggested that PKCδ activation plays a 
protective role in IR injury and that PKCδ knockout (KO) 
mice exhibit increased myocardial ischemic injury [146]. 
Moreover, it has been suggested that the activation of 
PKCδ before ischemia triggers a protective effect against 
myocardial IR alterations in both isolated perfused rat 
hearts and cultured cardiomyocytes [4].
In cancer cells, S727 phosphorylation has been observed 
during the canonical STAT3 activation, where it may have 
a role in enhancing the transcriptional activity of STAT3, 
for example by recruiting cofactors, such as the histone 
acetyltransferase p300/CBP or by promoting the homodimer 
formation [3]. Yet, some works have shown that phospho-
rylation of S727 drives a reduction of the levels of Y705 
phosphorylation in cancer cell lines. Yang et al. [234] dem-
onstrated that the phosphorylation of S727 triggers the dis-
sociation between pY705 and the SH2 domain of STAT3, 
thereby disrupting dimer formation. The phosphorylation of 
S727 enhances the dephosphorylation of Y705 by recruit-
ing phosphatase TC45, therefore, limiting the duration of 
STAT3 transcriptional activity in a human liver cancer cell 
line (HepG2) [234]. Similar studies are lacking in cardiac 
cells.
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STAT3 site Effects Reference
Phosphorylation Y705 Dimerization and translocation of the protein into the nucleus and constitutes the canonical 
pathway of STAT3 activation
[249]
Y705, S727 Promotes oncogenic activity of RhoA [11]
S727 Negatively modulates STAT3 Y705 phosphorylation [36]
S727 Extends the function of mTOR, including transcriptional regulation [239]
S727 Inactivates activated STAT3 leading to both pY705 dephosphorylation and post-activation 
nuclear export
[234]
Y705, S727 Stimulates respiration and inhibits calcium-induced MPTP opening, contributing to cardio-
protection
[20]
S727 Interacts with GRIM-19 to facilitate STAT3 mitochondrial localization [210]
S727 Activates complex I and II [225]
S727 Increases mRNA for complex I subunits and decreases ROS generation [243]
Y705 Increases mitochondrial respiratory capacity and biogenesis [1]
Y705, S727 Regulates ER Ca2 + homeostasis [9]
S727 Regulates mitochondrial metabolism [201]
S727 Moderates ROS levels in the post-ischemic phase [229]
Y705 Reduces infarct size in LAD-ligated pig hearts [100]
Y705 Increases Ca2 + retention capacity, preserves complex 1 respiration and reduces infarct size [79]
S727 Attenuates myocardial IR injury [250]
Y705 Regulates cardiomyocyte survival and remodelling [49]
Y705 Reduces infarct size in LAD-ligated pig hearts [191]
Y705 Reduces infarct size and improves lefte ventricle (LV) diastolic pressure [82]
Y705 Reduces IR injury in isolated rat hearts [38]
Y705 Involved in efferent vagal nerve activation and spleen stimulation, releasing humoral cardio-
protective substances
[133]
Y705 Less vacuolization of mitochondria in the children undergoing open heart surgery and 
RIPreC attenuating myocardial IRI
[230]
Y705 Determines hypothermia-induced protection in H9c2 cells [88]
Y705 Reduces infarct size in LAD-ligated rat hearts [45]
Y705 Reduces infarct size in LAD-ligated rat hearts [62]
Y705, S727 Anti-apoptotic effects on cardiomyocytes [187]
Y705 Ameliorates the contractile force in human atrial trabeculae exposed to H/R [125]
Y705 Reduces infarct size in in-vivo mouse hearts [7]
Y705 Reduces infarct size in in-vivo mouse hearts [160]
Y705 Attenuates cardiac fibrosis by regulating the macrophage polarization [123]
Y705 Reduces infarct size in isolated rat hearts [193]
Y705, S727 Improves LV contraction and decreases expression of pro-apoptotic proteins [47]
Y705 Reduces IR injury in ex-vivo and in-vitro models [53]
S727 Reduces IR injury in isolated mice hearts [197]
S727 Regulates mitochondrial respiration in in-vivo model [220]
S727 Mediates cardioprotection as a modulator of ETC activity in the mitochondria [206]
S727 Reduces infarct size in mice [18]
Y705 Reduces hypertrophy in rat model [29]
S727 Attenuates diabetic rat heart IR injury [217]
Y705 Limits diabetic cardiomyopathy in in-vivo and in-vitro models [203]
S727 Reduces infarct size in diabetic rats [131]
Y705 Reduces infarct size in rats [124]
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Acetylation
In response to stimulation by growth factors and cytokines, 
STAT3 can also be acetylated on multiple lysine residues 
(K) by histone acetyltransferase CBP/p300. Acetylation at 
K49, K87 (N-terminus) and K685 (SH2 domain) enhances 
STAT3-mediated gene transcription and protects cardio-
myocytes from doxorubicin (DOXO)-oxidative stress [91]. 
It has been also observed that acetylation in K87 may favor 
the translocation in mitochondria of STAT3 in starved can-
cer cells after serum reintroduction or insulin stimulation 
[232]. Yet, acetylation in K685 induces the transcriptional 
activity of STAT3 by increasing tyrosine phosphorylation 
and dimer stability in prostate cancer cell line (PC3) [241]. 
STAT3 acetylation is also involved in the improvement of 
mitochondrial morphology and function in neonatal mouse 
cardiac myocytes [156]. It has been shown that after resvera-
trol treatment, STAT3 acetylated in K685 can silence tumor 
suppressor genes by recruiting DNA methyltransferase 1 to 
their promoters [120]. Yet, the nicotinamide adenine dinu-
cleotide (NAD)-dependent silent information regulatory 
protein (SIRT) 1 can deacetylate STAT3 in the liver [159]. 
Of note, SIRT1-induced deacetylation leads to reduced 
mitochondrial localization and function of phosphorylated 
STAT3 in murine embryonic fibroblast cells [15].
Methylation
In the nucleus, STAT3 methylations have been described on 
the K140 or K180 residues, with different effects on STAT3 
activities. Histone methyltransferase SET9, a histone-mod-
ifying enzyme, is capable of methylating STAT3 on K140, 
leading to modulation of transcriptional activation of tar-
get genes in A4 cancer cells [233]. On the other hand, the 
enhancer of zeste homolog 2 (EZH2) component of the poly-
comb 2 complex determines K180 tri-methylation, which is 
essential for maintaining STAT3 phosphorylation and tran-
scriptional activity in glioblastoma and prostate cancer cells 
[90]. The majority of studies on acetylation and methylation 
have been performed on mammalian cancer cells.
Glutathionylation, oxidation, S‑nitrosylation 
and sulfhydration
STAT3 can be oxidized, S-nitrosylated, sulfhydrated and 
glutathionylated on multiple cysteine residues, suggesting 
that STAT3 controls redox homeostasis and ROS signaling 
induced by cytokines and growth factors. Using antioxidants 
in studying the effects of cytokines on cells or in stimulating 
cells (fibroblasts and A-431 carcinoma cells) with  H2O2, 
ROS have been shown to play a signaling role in the con-
trol of JAK, STAT3 and STAT5 [188]. The activation of 
STAT3 and STAT5 by ROS upon cytokine or growth fac-
tor treatment can also determine the activation of NADPH 
oxidase (Nox) in human aortic smooth muscle cells [92] 
and in cancer cells [240]. In particular, ROS inhibit STAT3 
transcriptional activity, either downstream of the IL-6 sig-
nal or in conditions of oxidative/nitrosative stress [107, 
132, 196, 231]. Of note, moderate ROS production down-
stream of growth factors such as insulin-like growth factor 
1 (IGF1) and EGF can activate JAK kinases and enhance 
STAT3 phosphorylation and its nuclear activity [35, 110, 
122, 188]. STAT3 oxidation can be observed downstream of 
cytoplasmic thiol peroxidase peroxiredoxin-2 (Prx2) [196]. 




STAT3 site Effects Reference
Acetylation K49, K87 (N-ter-
minus) and K685 
(SH2 domain)
Enhances STAT3-mediated gene transcription and protects cardiomyocytes vs doxorubicin-
oxidative stress
[91]
K370, K383 Improves mitochondrial morphology and function in neonatal mouse cardiac myocytes [156]
K685 Induces Y705 phosphorylation transcriptional activity of STAT3 by increasing and dimer 
stability in prostate cancer cell line (PC3)
[241]
K87 Favors the translocation and mitochondrial functions of STAT3 in starved cancer cells [232]
Methylation K140 dimethylation Decreases STAT3-dependent transcription in A4 cancer cells [233]
K180 trimethylation Stimulates STAT3 phosphorylation and transcriptional activity in glioblastoma and prostate 
cancer cells
[95]
Sulfydration no direct sulfydra-
tion detected on 
STAT3
Activates STAT3 by Y705 phosphorylation and protects cardiomyocytes vs doxorubicin-
oxidative stress
[228]
S-nitrosylation C259 Blocks Y705 phoshorylation in microglial cells [96]
Ubiquitination K97 Induces the recruitment of BRD4 and the transcription of anti-apoptotic genes in HepG2 
cells
[174]
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This limits ROS toxic effects, but impairs IL-6-induced and 
STAT3-mediated transcription. STAT3 sulfhydration favors 
STAT3 activation by Y705 phosphorylation and protects car-
diomyocytes from DOXO-oxidative stress [228]. Finally, 
S-nitrosylation at C259 blocks Y705 phoshorylation in 
microglial cells [96] and ubiquitination at K97 induces the 
recruitment of BRD4 and the transcription of anti-apoptotic 
genes in HepG2 cells. Thus, the inhibition of the STAT3 
mono-ubiquitination–BRD4 pathway may be useful for the 
treatment of STAT3-dependent tumors [174].
All in all, it appears that a cross-talk between oxidative 
and non-oxidative modifications of STAT3 can influence 
canonical and unconventional STAT3 activities, including 
cell proliferation and survival. The complex functions of 
STAT3 in redox homeostasis have recently been reviewed 
[8, 102, 134].
STAT3 in the SAFE Pathway
Post-translational modification of STAT3 is a pivotal step 
in the SAFE pathway in which TNFα and its receptors play 
key roles. As said this pathway can be activated in conjunc-
tion with the RISK pathway and it has been proposed to 
play a more important role in larger mammals [70, 79, 189, 
190]. Here we point out some aspects of SAFE in relation 
to STAT3.
First, it has been observed that in rodent hearts TNFα 
protects against IR in a dose-dependent manner [43, 112, 
117]. Besides TNFα, other agonists have been suggested in 
SAFE signaling, including high density lipoprotein (HDL), 
sphingosine-1-phosphate (S1P), IL-10, insulin and stromal 
cell-derived factor-1 alpha [26, 27, 46, 52], to name a few. 
Furthermore, TNFα emerged as an important cardioprotec-
tive endogenous factor released by cardiomyocytes during 
IPreC and IPostC maneuvers [113, 118]. Two isoforms of 
the TNFα receptor have been described in the heart, the 
TNFR1 and the TNFR2. Intriguingly, exogenous TNFα 
induces cardioprotection in TNFR1 KO mice, but is unable 
to protect TNFR2 KO mice, thus suggesting that cardiopro-
tection is mediated by TNFR2 activation [114]. In addition, 
it appears that TNF-receptor-associated-factor 2 (TRAF2) is 
the downstream target of TNFR2 in mice [24]. Yet, TRAF2 
is able to activate the formation of the S1P via sphingosine 
kinase 1 (SK1) activity [5] and the protective effect of TNFα 
is blunted in the presence of the sphingolipid pathway inhib-
itor, N-oleoylethanolamine [28]. These data suggest that S1P 
can act as a downstream target of TNFα/TNFR2/TRAF2 to 
confer cardioprotection [117]. TNFα binding to its specific 
receptors activates the JAK-STAT3 pathway. In particular, 
JAK2 phosphorylates and makes a docking site for STAT3 
which, after phosphorylation is activated (Fig. 2). Of note, 
it has been proposed that TNFα is able to induce Y705 
phosphorylation even if the interaction between TNFR2 
and JAK2 is still uncovered [63]. Indeed, this interaction 
could result in the activation of intracellular SK1 and S1P 
production in cell lines [5]. Following the binding of TNFα 
to TNFR2, the activation of TRAF2 could upregulate SK1, 
which in turn could catalyze the formation of intracellular 
S1P and the subsequent activation of JAK-STAT3 (Fig. 2).
In the next chapter, we analyze the mitochondrial function 
affected by IR and the role of STAT3 in affecting mitochon-
dria function. Indeed, mitochondrial targeting is essential in 
the SAFE pathway.
Mitochondrial functions affected by IR
Before to analyze the mitochondrial STAT3 role we briefly 
describe the role of mitochondria in IRI (for more details 
the reader is redirect to other review, e.g., [69, 76–78, 162, 
164],).
Under physiological conditions, mitochondria guarantee 
energy requirements, while under stressful conditions, they 
represent the judges of cell fate between life and death [128]. 
The heart is a high-energy-consuming organ as cardiomyo-
cytes contain a large number of mitochondria (about 30–40% 
in volume). Therefore, the heart will be heavily affected by 
the inefficient supply of oxygen and the consequent altera-
tion of the mitochondrial status.
During ischemia, the metabolism of myocardial tissue, 
initially mainly aerobic, turns towards an anaerobic pheno-
type. The mitochondrial metabolism is compromised by a 
drop in intracellular pH and a strong reduction in the ATP 
production [74]. ATP depletion causes a sensible reduction 
of the activity of  Na+/K+-ATPase, and other ion pumps 
fundamental for the maintenance of the physiological mito-
chondrial membrane potential (∆Ψm), including the  Na+/
H+ exchanger, the  Na+/Ca2+ exchanger and the L-type  Ca2+ 
channel [202]. In particular, the activation of L-type  Ca2+ 
channel contributes to  Ca2+ overload, with subsequent acti-
vation of nucleases, proteases and phospholipases. Another 
crucial event characterizing both ischemia and reperfusion 
is the ROS production, which derives from altered activity 
of both ETC and enzymes, such as xantine oxydase (XO), 
NADPH oxidase, cytochrome P450 oxidases, uncoupled 
nitric oxide synthase (NOS), and monoaminooxidase (MAO) 
[42]. All of these changes lead to depression of respiratory 
chain complex activity, inappropriate oxidative phospho-
rylation and ATP synthesis by F1F0-ATPase, that in turn 
determine a reduction in ∆Ψm, an additional  Ca2+ overload, 
the ROS-induced ROS release (RIRR) phenomenon, mito-
chondrial swelling and cytochrome c release promoting cell 
death [180, 202].
Upon reperfusion, and in particular immediately in the 
first phase, compared to ischemia, ROS production may lead 
to the peroxidation of mitochondrial respiratory complexes, 
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including the SH groups of complex I and cardiolipin, which 
is needed for complex III and complex IV activity. In IR 
setting the F1F0-ATPase not only reduces the production 
of ATP but may also reverse its operation by hydrolyzing 
the ATP present as the proton motive force that pushes the 
ETC is dissipated [143]. Therefore, the loss of ATP dur-
ing IR is further exacerbated [67]. Of note, F1F0-ATPase 
pump is recognized as the main component of mPTPs [14]. 
Despite the controversy surrounding the components that 
make up mPTPs, there is greater consensus on the triggers 
that induce their opening. Conditions such as  Ca2+ overload, 
excessive ROS production, ATP depletion and an increase 
in inorganic phosphate contribute to a large extent to their 
opening [162]. mPTPs opening is favored by pH recovery 
during reperfusion [89] with a subsequent collapse of the 
inner membrane, decoupling of the respiratory chain, arrest 
of mitochondrial ATP synthesis, and ultimately mitochon-
drial swelling, rupture, and cell death. The pharmacological 
inhibition of mPTPs opening at the beginning of reperfusion 
can attenuate cardiomyocyte death and reduce myocardial IS 
[25, 162]. Of note, F1F0 ATPase and mPTPs may also have 
a role in triggering IPreC [68, 169].
As said above and as reported in Fig. 1, three main signal-
ing cascades that converge to mitochondria have been identi-
fied in the context of IPreC and IPostC. It has been proposed 
that glycogen synthase kinase-3β (GSK-3β) acts directly on 
components on the mPTPs as well as on Bcl-2 family pro-
teins [164]. Moreover, the cGMP-PKG pathway may lead 
to the phosphorylation of mitochondrial PKCε1, which pro-
mote the opening of the mitochondrial ATP-sensitive  K+ 
channel  (mitoKATP) [55]; once opened, these channels allow 
increased uptake of  K+ in the matrix, leading to alkalini-
zation of the mitochondrial membrane. To counterbalance 
this event, Complex I of ETC increases its activity and pro-
duces more superoxide and its products  H2O2 and hydroxyl 
anion radical. The increased ROS are able to activate another 
PKC, PKCε2, which in turn will inhibit the mPTPs with 
a phosphorylation-dependent reaction, thereby preserving 
mitochondrial functionality [164].
Mitochondria are dynamic organelles that continually 
change their shape by undergoing quality control mecha-
nisms, that include mitochondrial fission, fusion and 
mitophagy, a specialized form of autophagy; these are fun-
damental processes to maintain mitochondria turnover and 
assure metabolic need of cardiomyocytes [76, 162]. Upon IR 
stressful conditions, mitochondria may activate these quality 
control mechanisms. Thus removing defective mitochondria 
and restoring the energetic balance, to protect cardiomyo-
cytes against IRI. Mitophagy should be finely regulated to 
maintain a favorable balance between dying mitochondria 
and new functional mitochondria, which should restore ATP 
production. During IR excessive mitochondrial fission may 
lead to cardiomyocyte death. In particular, dynamin related 
protein-1 (DRP1), the regulator of mitochondrial fission, is 
able to recruit Bax/Bak and promotes the mPTP formation at 
the outer mitochondrial membrane, triggering cytochrome c 
release. In addition, mitochondrial fusion may provide a pro-
tective effect during IR, by counterbalancing the excessive 
mitochondrial fission, and equilibrating mitochondrial pro-
teins and mitochondrial DNA (mtDNA) [104]. In this con-
text, STAT3 may play a pivotal role (Fig. 2) as we describe 
below (see also “Effects of STAT3 on mitochondrial quality 
control”).
Effects of STAT3 on mitochondrial function
STAT3 non-genomic functions raise still some questions 
about how, where, and when its action is exerted. In par-
ticular, in cardiac IRI models, mitochondria are the most 
interesting target of the investigation, since they are highly 
represented and can determine the life and death of cardiac 
cells. Besides mitochondrial quality control, ETC, ΔΨm, 
 Ca2+ regulation, redox balance, and mPTPs status are prom-
ising targets that can be affected by STAT3 non-genomic 
function.
Localization of STAT3 in mitochondria. To investigate 
the role of STAT3 in mitochondria, it is necessary to verify 
its localization and how it is redirected and translocated 
in mitochondria. Even before the discovery of the SAFE 
pathway, several research groups studied the interaction of 
STAT3 with candidate proteins and their localization in mice 
and rats cardiomyocytes [65, 93, 229]. The interest started 
in the contest of cancer research, focusing on finding mol-
ecules able to interact and inhibit the transcriptional activity 
of STAT3, which is known to regulate cell growth and apop-
tosis and is constitutively active in various cancers [119]. 
Even if the cellular models are different, the identification 
of interactors of STAT3 has been the first step to understand 
the mechanisms promoting the mitochondrial localization 
of STAT3 in cardiac cells. Several evidences obtained with 
techniques, such as Yeast two-hybrid, co-immunoprecipita-
tion, and immunofluorescence, suggest that the main mito-
chondrial interactor of STAT3 is gene associated with reti-
noid interferon-induced cell mortality 19 (GRIM19) [140].
Phosphorylation of mitochondrial STAT3. Zhang et al. 
[244] found that the mutagenesis of S727 into alanine deter-
mines the suppression of the interaction with mitochondrial 
GRIM19 in HeLa cells. Therefore, phosphorylation of S727 
sites has been proposed as necessary for mitochondrial 
localization (Fig. 2). Nevertheless, the timing and nature of 
STAT3 phosphorylation should still be determined, to under-
stand if the phosphorylation occurs outside or inside the 
mitochondria and if phosphorylation of S727 is fundamental 
in determining the import in mitochondria. Boengler et al. 
[20], among others, found that STAT3 phosphorylated at 
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both Y705 and S727 and co-immunoprecipitated with trans-
locase of the outer membrane 20 (TOM20) in mitochondria 
extracted from the rat left ventricle.
Import into mitochondria and interacting mitochondrial 
proteins. Zhang et al. [244] showed that GRIM19, in dif-
ferent cancer cell lines, interacts specifically with STAT3 
but not with other STAT proteins, such as STAT1 and 
STAT5A. This selectivity may be due to the differences 
that STAT family members bear in the TAD, which deletion 
prevents the co-immunoprecipitation of these two proteins. 
Although the aim of Zhang et al. [244] was to demonstrate 
that GRIM19 was able to inhibit the genomic function of 
STAT3 in the tumorigenesis progression, subsequently 
Tammineni et al. [210] found that STAT3 is enriched in the 
inner mitochondrial membrane isolated from rat heart and 
suggested that GRIM19 influences STAT3 integration into 
complex I. Indeed, GRIM19 was found to promote STAT3 
import into mitochondria and to favor STAT3 integration 
into complex I. As said, these two events may depend on 
the S727 site of STAT3 C-terminus. Indeed, in mitochondria 
from rat hearts, the deletion of the C-terminus and the muta-
tion of serine 727 into alanine (S727A) abolished the import 
of STAT3 and the assembly into complex I [210]. Even if 
STAT3 lacks the mitochondrial targeting sequence required 
for the mitochondrial import, TOM20 has been proposed to 
recognize STAT3 and mediate its translocation inside the 
mitochondria [20].
Despite these evidences, some studies did not find STAT3 
in the mitochondrial fraction of mice hearts [65]. Some of 
these works investigated the hypothesis that STAT3 may 
exert its non-genomic function in other non-nuclear sites, 
such as in the ER. For instance, Su et al. [201] demonstrated 
that STAT3 is present in the mitochondrial-associated ER 
membrane (MAM) of different tissues (liver, lungs, brain). 
A data confirmed by Avalle et al. in cancer cell lines [9] (see 
below “Effects of STAT3 on  Ca2+ regulation”).
Effects of STAT3 on mitochondrial ETC
As mentioned before, mitochondrial damage occurring 
during ischemia can be partially explained by the altera-
tion of ETC functionality, followed by enhanced ROS gen-
eration during reperfusion [205]. It is possible to induce 
cardioprotection by targeting ETC complexes and regu-
lating mitochondrial respiration. STAT3 has been shown 
to interact with ETC complex I and II, preserving their 
activity in mitochondria from mice hearts and enhance 
ATP production in human cancer cells [61, 225]. As result, 
aerobic cellular respiration would be optimized, and ROS 
formation would be under control (Fig. 2). Particularly, 
Wegrzyn et al. [225] considered the role of STAT3 in cel-
lular respiration. First, they verified the mitochondrial 
and submitochondrial location of STAT3 in cells isolated 
from mouse heart, brain, kidney, spleen as well as human 
cell lines. One-tenth of the cellular STAT3 has been found 
in the mitochondrial fraction of these cells. STAT3 and 
GRIM19 resisted the proteinase K treatment of isolated 
mitochondria, indicating that they may be located in the 
inner membrane or the matrix, rather than in the outer 
membrane. STAT3 co-immunoprecipitated with compo-
nents of complex I and II, which activity was then meas-
ured in the absence and presence of STAT3. Cardiomyo-
cytes from STAT3-deficient mice showed a decreased rate 
of  O2 consumption as well as reduction of complex I and 
II activity, but not complex III. In STAT3-deficient pro-B 
cells the loss of complex I and II activity was restored by 
both full-length STAT3 and by MLS-STAT3, the mito-
chondrial form of STAT3. The latter is obtained by add-
ing the mitochondrial targeting sequence of cytochrome c 
oxidase subunit VIII to STAT3. A mutagenesis study of 
MLS-STAT3 then revealed that the S727, but not the Y705 
site was fundamental to mediate the activation of complex 
I and II [225].
However, it is still unclear whether the control of mito-
chondrial localization, complex I/II association, or other step 
might be responsible of the STAT3 regulation of the respira-
tion [154]. Whether such a regulation pertains to STAT5 in 
different species is alternatively discussed [245].
Direct interactions between STAT3 and complex III and 
IV were not found; however, the existence of mitochondrial 
respiratory supercomplexes formed by complex I, III, and 
IV [128] does not allow to rule out the influences of STAT3 
on these supercomplexes. Contradictory results are reported 
regarding the ability of STAT3 to decrease ROS generation 
by complexes I and III of the ETC in mitochondria from 
mice left ventricular tissue [21]. The low ratio between com-
plexes I and II and STAT3 in mitochondria of porcine and 
murine hearts [170] is against the hypothesis that STAT3 
might be a structural component of these complexes. There-
fore, further analyses are required to determine the nature of 
the interaction between STAT3 and the proteins of the ETC.
Other studies investigated whether different molecules 
improve the recovery of mitochondrial function after IRI 
through STAT3 signaling within mitochondria. For instance, 
Zhang et al. [243], used Zinc either on isolated rat hearts or 
H9c2 cardiomyoblasts subjected to IR or Hypoxia/Reoxy-
genation (H/R), respectively. They observed that Zinc 
treatment leads to increased phosphorylation of STAT3 at 
S727 compared to Y705. Yet, the balance of cytosolic and 
mitochondrial STAT3 was in favor of the latter, suggest-
ing that the phosphorylation of S727 could direct STAT3 
towards mitochondria. Moreover, it has been shown that 
Zinc-induced S727 phosphorylation is involved in the 
enhancement of mitochondrial oxidative phosphoryla-
tion. Particularly, in isolated rat hearts exposed to IR, Zinc 
induced a sensible improvement of the rate of respiration, 
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which determined an increased ATP level and citrate syn-
thase activity. These data are supported by an increase in 
mRNA for complex I subunits and a decrease in ROS gen-
eration [243].
The mechanism by which STAT3 interacts with Com-
plexes I and II is still unknown; there is contrasting evi-
dence about whether mitochondrial STAT3 can modulate 
the levels of mRNA of these complexes, but in the majority 
of the cases, the mRNA levels are unchanged in presence or 
absence of mitochondrial STAT3. Intriguingly, STAT3 was 
found to bind mtDNA in several cell types and to interact 
with mitochondrial transcription factor TFAM in keratino-
cytes, where it regulates the level of some mitochondrial-
encoded transcripts, such as NADH dehydrogenase 5/6 and 
cytochrome b [142]. Of note, the prevention of mtDNA 
degradation has proven to be cardioprotective in in vivo 
and ex vivo rat hearts [237]. Nevertheless, to the best of 
our knowledge, despite STAT3 binding to mtDNA, no evi-
dence has been reported on the role of STAT3 in influencing 
mitochondrial-encoded transcript and/or mtDNA degrada-
tion in the context of cardioprotection. Further investigation 
is required to elucidate the exact pathway by which STAT3 
affects mitochondrial ETC.
Effect of STAT3 on ROS generation
The mitochondrial redox state is determined by the balance 
between the production of reactive species by the ETC and 
the other sources of ROS indicated above on the one hand 
and the scavenging of ROS by antioxidant enzymes on the 
other hand.
For instance, during IR events, ETC is altered and conse-
quently, ROS production is increased and further sustained 
by the RIRR. This leads to cardiolipin peroxidation at the 
inner membrane that favors mPTPs opening and cytochrome 
c release from mitochondria, promoting apoptosis [212]. 
Studies in cardiomyocytes showed that DOXO treatment 
caused a reduction of the complex I in mitochondria, as 
well as increased production of ROS [247]. The cardiac-
specific overexpression of STAT3 led to a decreased toxicity 
of DOXO in mice and in primary ventricular murine cardio-
myocytes [106, 177], suggesting that STAT3 may be able to 
attenuate ROS formation, even if its precise mitochondrial 
function has not yet been discovered. Studies report a strong 
inhibition of complexes I and II in cardiac tissues [225] and 
a low membrane potential, a decreased ATP level and an 
increased ROS formation in the absence of mitochondrial 
STAT3 in astrocytes [181].
It is not clear how STAT3 can promote mitochondrial res-
piration and at the same time minimize ROS formation. Szc-
zepanek et al. [205] speculate that during ischemia STAT3 
is able to reduce the levels of superoxide produced by com-
plex I, and to address, decreasing cardiolipin oxidation, the 
superoxide towards the mitochondrial matrix, thereby pro-
tecting the inner membrane and preventing the release of 
cytochrome c. This speculation was supported by the obser-
vation that cardiomyocytes overexpressing mitochondrial-
targeted STAT3 had reduced ROS levels in comparison with 
wild type mitochondria upon ischemia. Additional evidence 
supporting that STAT3 is able to keep ROS under control is 
provided by Boengler et al. [20], who treated mitochondria 
extracted from rat left ventricles with the STAT3 inhibitor 
Stattic. In this case, the inhibition of STAT3 induced a dose-
dependent increase in ROS formation from complex I, which 
was coupled with lower ATP production and  Ca2+ retention 
capacity. Nevertheless, further research is needed as Stattic 
is not specific for mitochondrial STAT3 [183]. Moreover, 
we cannot rule out that STAT3 genomic function contrib-
utes to reducing ROS formation by altering the transcrip-
tion of genes encoding scavenging proteins. An interesting 
study about the relationship between STAT3 and ROS is 
provided by Abid et al. [1]. They demonstrated that IL-6 
exposure activates the canonical STAT3 pathway in myo-
tubes favoring mitochondrial ROS formation and STAT3 
Y705 phosphorylation, determining a sort of positive feed-
back between these two events. As a result, mitochondrial 
respiratory capacity and biogenesis were acutely increased. 
However, a decline in respiration and a further elevation in 
ROS and oxidative stress was observed when IL‐6 exposure 
was sustained [1].
Effects of STAT3 on mPTPs opening
The most critical challenge to safeguard cardiac cell function 
during IR stress is to maintain the mitochondria integrity. 
As mentioned before, the opening of mPTPs is a crucial 
step leading to cell death and it occurs mainly during rep-
erfusion of cardiac tissue, as a consequence of the dam-
age caused by ROS and  Ca2+ overload [108]. The point is 
discussed by Boengler et al. [20], who investigated the role 
of STAT3 in isolated mitochondria from cardiomyocyte-
specific  STAT3−/− mice and in isolated rat heart mitochon-
dria using the inhibitor Stattic. Mitochondria isolated from 
 STAT3−/− hearts undergo mPTPs opening upon exposure to 
lower  Ca2+ levels compared to  STAT3+/+ hearts [20]. There-
fore, it can be hypothesized that  STAT3−/− mitochondria are 
more susceptible to reperfusion-induced damage when  Ca2+ 
overload triggers mPTPs opening (Fig. 2). Indeed, IPreC and 
IPostC, which rely on the limitation of mPTPs opening at the 
beginning of reperfusion, do not trigger cardioprotection in 
mouse  STAT3−/− hearts [113, 194]. The reason behind this 
protective role of STAT3 is still unknown, but some possible 
hypotheses relate to the interaction of STAT3 with cyclophi-
lin D (CypD), a mitochondrial protein identified as a regula-
tor of mPTPs [151]. This binding is mediated by the amino 
terminus of STAT3, suggesting that other domains (amino 
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acids 1–330 of STAT3) in mitoSTAT3 are relevant for its 
non-canonical mitochondrial role. The interaction STAT3-
CypD occurs in the mitochondria with subsequent reduc-
tion of mitochondrial ROS production after oxidative stress 
[151]. As said above, another hypothesis is that STAT3 binds 
to the NTD of the mitochondrial  Ca2+ uniporter (MCU) to 
reduce mitochondrial  Ca2+ overload and thus ROS produc-
tion in rat hearts and cardiomyocytes [229]. Nevertheless, a 
reduction of ROS formation may limit mPTPs opening and 
the RIRR phenomenon [212].
Effects of STAT3 on  Ca2+ regulation
Calcium regulation is one of the main events that denote the 
cell functionality; therefore, its concentration in different 
subcellular compartments is finely controlled. In the ER, 
 Ca2+pump (SERCA), IP3R and their relative ryanodine 
receptors represent the gates that allow the entry and the 
release of  Ca2+, respectively [32], while in the mitochondria, 
 Ca2+ concentration is important to regulate the activity of 
enzymes, the rate of respiration and to maintain mPTPs sta-
tus. It has been proposed that STAT3 may have an important 
role in the closed relationship between ER and mitochondria. 
In this regard, Avalle et al. [9] showed that STAT3 interacted 
with IP3R3 on the ER and that its mutation in S727, but 
not in Y705, determined an excessive release of  Ca2+ in 
the cytosol of breast cancer cell lines. They explained this 
observation by demonstrating that STAT3 promoted IP3R3 
proteasomal degradation. Moreover, STAT3 silencing in 
STAT3-dependent MDA-MB-468 and -231 cells also signifi-
cantly increased  Ca2+ content and release from the ER [9]. 
On the other hand, in MDA-MB-453 or T47D cells, in which 
STAT3 is not active, the release of  Ca2+ was not modified 
by the silencing of STAT3. Therefore, in STAT3-dependent 
cells, treatment with  H2O2 or menadione increased  Ca2+ 
release. It appears that STAT3 can regulate ER  Ca2+ homeo-
stasis when phosphorylated on both Y705 and S727 by local-
izing to the ER and MAM, where it physically interacts with 
the IP3R3  Ca2+ channels [9] (Fig. 2). IP3R is also known to 
mediate the interaction between MAM and voltage-depend-
ent anion channels (VDAC) on the mitochondrial membrane 
[32]; therefore, is not excluded that STAT3, which has been 
found in the MAM context [201], may be involved in this 
cross-talk. In other words, the preservation of  Ca2+ homeo-
stasis by S727-phosphorylated STAT3 in the ER represents 
an indirect mechanism of mitochondrial metabolism regu-
lation. Another evidence of STAT3  Ca2+ regulation is pro-
vided by Yang et al. [235], who examined the alterations of 
mitochondrial  Ca2+ in  STAT3+/+ and  STAT3−/− CD4 cells 
under IL-6 stimulation. They found that IL-6 promoted an 
increase in mitochondrial  Ca2+ and that STAT3 was able to 
reduce its mitochondrial concentration, by promoting the 
 Ca2+ export to the cytosol. This action was independent of 
the transcriptional activity of STAT3, but more likely elic-
ited through mitochondrial STAT3.
It has been reported that MCU transports significant 
amounts of  Ca2+ from the cytosol into mitochondria [51]. 
The activity of MCU may be influenced by STAT3. Indeed, 
it has been reported that during IPostC obtained with  H2O2, 
STAT3 interacts with the N-Terminal Domain (NTD) of 
MCU in rat cardiomyocytes [229]. Moreover, a co-localiza-
tion and interaction of STAT3 phosphorylated at S727 and 
MCU was observed in these cardiomyocytes. These results 
indicated that moderate ROS levels in the post-ischemic 
phase could activate STAT3 which inhibits the MCU via its 
interaction with the NTD of MCU to relieve mitochondrial 
 Ca2+ overload [229].
Effects of STAT3 on mitochondrial quality control
TNFR2 activation protects cardiac myocytes against stress 
by upregulating optic atrophy 1 (OPA1) expression. This 
process was facilitated by p300-mediated STAT3 acetylation 
and STAT3/RelA interactions, leading to improvements in 
mitochondrial morphology and function [156]. Yet, κ-opioid 
receptor activation promotes mitochondrial fusion and 
enhances myocardial resistance to ischemia and reperfusion 
injury via STAT3-OPA1 pathway [219]. Since mitochondrial 
quality control plays a vital role in cardioprotection, further 
investigations are needed to clarify the exact involvement of 
STAT3 in this process.
All in all, we can say that STAT3 plays a pivotal role in 
regulating mitochondrial function, fundamental organelles 
for the cardioprotection by conditioning procedures. Since 
STAT3 is central in the SAFE pathway, the activation of 
this pathway is necessary for the cardioprotective effect of 
ischemic conditioning in some species and conditions [19, 
98, 101]. In the following Section we discuss these aspects.
STAT3 in cardiac conditioning
As mentioned in the introduction, here we update the role 
that STAT3 plays in the context of different conditioning 
strategies, including IPreC, IPostC, pharmacological/hypo-
thermic conditioning and RIC. The latter can be induced 
before (RIPreC), during (RIPerC) or after (RIPostC) the 
myocardial infarcting ischemia (Fig. 1). In all these proce-
dures the involvement of STAT3 has been described. Indeed, 
TNFα or STAT3 cardiomyocyte KO are not protected by 
ischemic conditioning stimuli, but it is still possible to 
induce pharmacological conditioning [113, 118, 194, 195]. 
Therefore, some differences among procedures and species 
exist, as we will see, for example, considering the parallels 
between STAT3 and STAT5.
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STAT3 in ischemic preconditioning
As said, IPreC, defined as non-lethal episodes of myocar-
dial IR applied before an ischemic event, is the first condi-
tioning maneuver discovered more than 35 years ago [153]. 
Clinical evidence of the efficacy of IPreC in human hearts, 
supported by parameters, such as attenuated ECG changes, 
reduced lactate and creatine kinase release, are provided by 
the review of Heusch and Rassaf [81].
The comprehensive article of Kleinbongard [100] com-
pared IPreC, IPostC and RIPreC in relation to the phospho-
rylation of different proteins involved in cardioprotection, 
including STAT3, Akt and ERK1/2. The phosphorylation of 
STAT3 in Y705 occurred at both 10 min and 120 min of rep-
erfusion post left anterior descending artery (LAD) ligature 
only in pig’s hearts exposed to IPrec and not to IPostC nor 
RIPreC. Since any other signaling pathways were upregu-
lated, STAT3 activation was associated with cardioprotective 
properties of IPreC in pigs.
The same result is confirmed by some other studies in 
pigs [57], but questioned by another study [200], in which 
the specific inhibition of ERK signaling and not STAT3, 
abrogated IPreC-mediated cardioprotection in pigs. Yet, 
Kwak et al. [109] reported that the protective mechanisms of 
sodium nitroprusside (SNP, 0.3 mM) preconditioning against 
high-concentration-SNP (1.5 mM)-induced apoptosis in 
H9c2 cardiomyoblasts was mediated by ERK1/2-STAT1/3 
activation via PKC-dependent mechanisms. Indeed, in this 
model chelerythrine, a PKC antagonist, abolished the acti-
vation of both ERK1/2 and STAT1/3. Bolli et al. [23] used 
an inducible cardiomyocytes-specific STAT3 KO mouse to 
determine the role of STAT3 in mediating the IPreC-pro-
tection versus in vivo LAD ligation. In this study, IPreC 
upregulation of cardioprotective proteins, such as Heme oxy-
genase 1 and Cyclooxygenase-2 and antiapoptotic proteins 
(Bcl-xL and Mcl-1, c-FLIPL and c-FLIPS), was abrogated 
in cardiomyocytes-specific STAT3 KO mouse [23]. These 
experiments by Bolli and coll. [23] provide insight on the 
fundamental role of STAT3 in inducing cardioprotection in 
the late phase of IPreC and, therefore, its deletion abrogates 
all of these protective effects.
STAT3 in ischemic postconditioning
IPostC refers to brief repeated cycles of ischemia and rep-
erfusion that are applied at the ischemic site immediately 
after reperfusion [248]. IPostC may reduce IS, edema and 
improve left ventricle (LV) contractile properties in clinical 
studies [211]. However, other studies do not support these 
cardioprotective potentials (see below, “Some more consid-
erations on mitochondrial STAT3 in IRI and cardioprotec-
tion” and “Effects of common risk factors and confounders 
on STAT3 cardioprotection”). 
The mechanisms of protection may be similar to IPreC, 
i.e., SAFE and RISK pathway, but IPostC protection may 
rely also on other pathways, which control redox state 
and pH, as well as on mitochondrial players influenced by 
STAT3. In this regard, Heusch et al. [79] studied the phos-
phorylation of STAT3 and the mitochondrial activity in 
pig hearts subjected to IR followed by IPostC. In isolated 
mitochondria from postconditioned hearts, STAT3 phospho-
rylation in Y705 was increased and they observed increased 
 Ca2+ retention capacity and preserved complex 1 respira-
tion in comparison with mitochondria from non-conditioned 
hearts. All these effects, including the decreased IS were 
reverted with the use of AG490, a specific and potent inhibi-
tor of the JAK2/STAT3 pathway.
Zhu et al. [250] found that IPostC, in primary rat ven-
tricular cardiomyocytes exposed to H/R, is able to reduce 
H/R-induced cell damage, with concomitant enhancement 
of STAT3 phosphorylation S727 but not at Y705. These 
authors were interested in the involvement of 5' Adenosine 
Monophosphate-activated protein kinase (AMPK) in IPostC 
and they found that STAT3 phosphorylation was not affected 
by the inhibition of AMPK, as well as the protective effects 
of IPostC were not abrogated, suggesting that IPostC in vitro 
relies on STAT3 and this is independent of AMPK sign-
aling. In vivo model of MI achieved with LAD occlusion 
gave similar results with IPostC, increasing the level of S727 
but not Y705 phosphorylation of STAT3 [250]. Moreover, 
they compared IPostC to pharmacological postconditioning 
with Adiponectin and they found that while IPostC induced 
STAT3 activation by S727 phosphorylation, the latter acti-
vated/phosphorylated STAT3 in Y705, supporting the differ-
ence between ischemic and pharmacological conditioning. 
Interestingly, the combination of IPostC and Adiponectin 
conditioning provided additional protection in comparison 
with the conditioning alone, and promoted the phosphoryla-
tion of both sites of STAT3 [250]. This suggests that the 
integration of canonical pathway of STAT3 (transcription 
of antioxidant and anti-apoptotic genes) with the mitochon-
drial pathway (reduction of ROS production, mPTPs open-
ing prevention, optimization of complex I activity) is able 
to provide maximal cardioprotection in vivo.
STAT3 in remote ischemic conditioning
Remote ischemic conditioning is performed by applying 
brief cycles of IR in a remote organ or tissue from the heart; 
it was demonstrated to protect the heart against subsequent 
ischemic events, not only in animal models, but also in 
humans and it is currently under studies in the clinic [33, 
85, 171].
STAT3 signaling was activated in mice hearts subjected 
to LAD ligation, when RIPostC was applied in the left hind 
limb at the beginning of reperfusion [54]. Apoptosis and 
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oxidative stress markers were decreased in the RIPostC 
group, but these protective effects were abrogated when 
mice underwent AG490 pre-treatment and STAT3 was 
inhibited. Accordingly, Billah and colleagues [16] study-
ing the link between STAT3 and autophagy in H9c2 cells 
and rats, subjected to RIPreC and H/R and IR, respectively, 
found that RIPreC applied prior to IR reduced the IS and 
upregulated autophagy in heart tissue at 24 h post-RIPreC. 
Interestingly, they detected the activation of STAT3 and 
an increased plasma level IL-6 immediately after RIPreC, 
indicating that JAK/STAT3 signaling occurs upstream to 
autophagy upregulation. Besides, pretreatment with AG490 
abolished RIPreC-induced autophagy upregulation in vitro. 
These results suggest STAT3-dependent autophagy activa-
tion as a putative mechanism for RIPreC cardioprotection. 
In another study with a similar model, the same group found 
that the RIPreC-induced increase in IL-6 plasma level and 
subsequent JAK-STAT pathway activation, was dependent 
on the early growth response-1 (Egr-1) transcription factor 
[17]. The silencing of Egr-1 led to a decrease in STAT3 
Y705 phosphorylation and an increase in hypoxic damage 
in vitro and IS in vivo. Both these two studies highlight the 
importance of the increase of plasma IL-6 secretion after 
RIPreC to protect the heart against IRI. Yet, it has been pro-
posed that IL-6 can signal in cardiomyocytes independently 
of STAT1/3 and that the activation of ERK1/2 and PI3K by 
IL-6 is required for inducing cardioprotection. Consistently, 
IL-6 induces the activation of MAPKs and in particular of 
p38-MAPK, which acts as negative feedback regulator of 
JAK/STAT activation in cardiomyocytes [49]. Indeed, the 
inhibition of p38-MAPK enhances STAT3 phosphorylation. 
This suggests that a balance exists between MAPKs and 
JAK/STAT in cardiomyocyte survival.
An interesting study of Skyschally et al. [191] focused 
on RIPerC and its mechanism of protection in pigs, rats 
and mice. RIPerC in pigs exerted a cardioprotective effect, 
whose magnitude was similar to the one induced by RIPreC 
[190, 191]. In both experiments, the conditioning maneu-
vers provided the same results in terms of protection by 
activating STAT3 but not RISK pathway in pig hearts, as 
indicated by low levels of Akt and ERK1/2 phosphoryla-
tion. The transfer of plasma from pigs who underwent either 
RIPerC or RIPreC, to isolated mice or rat hearts, protected 
these hearts from the ex vivo IR. Intriguingly, the transfer 
of humoral factors contained in the pig plasma, activated 
both RISK and SAFE pathways in rodent’s hearts and both 
pathways were fundamental to reduce IS. In isolated rat car-
diomyocytes, the transfer of pig plasma helped to preserve 
complex I mitochondrial respiration, improve mitochondrial 
ATP production and reduce ROS formation. These effects 
were abolished by the use of both RISK and SAFE pathway 
inhibitors. To investigate whether RIC induces the release 
of cardioprotective factors also in humans, Hildebrandt et al. 
[82] harvested the plasma from healthy volunteers undergo-
ing RIC from 5 min post procedure up to 6 days. The plasma 
was subsequently given to isolated mice hearts before the 
induction of IR and revealed to be protective and reduce IS 
up to 50%. An increased STAT3 phosphorylation, but not 
Akt and ERK1/2, was detected in mice hearts treated with 
the RIC-plasma and the additional treatment with STAT3 
inhibitor Stattic abrogated the cardioprotection. The above 
studies suggest that STAT3 is crucial in pigs and humans, 
whereas RISK is involved in rodents only. The different 
effects of humoral factors of animal or human plasma in 
rodent’s hearts may be due to the inter-species transfer dif-
ferences. In addition, the signal transduction may be differ-
ent in healthy or diseased subjects, in which confounding 
factors are present (See also below “Effects of common risk 
factors and confounders on STAT3 cardioprotection”).
Differently from the Hildebrandt et al. study [82], in 
which healthy volunteers were enrolled, in a recent clinical 
trial the effect of humoral factors of patients suffering acute 
coronary syndrome (ACS) has been evaluated [38]. In this 
study the role of STAT3 in inducing cardioprotection has 
been demonstrated. In particular, extracellular vesicles (EV) 
were collected from ACS patients without or with RIPreC 
before percutaneous coronary intervention (PCI) and tested 
in-vitro and an ex-vivo IR models [38]. EV recovered from 
non-preconditioned patients induced protection against IRI, 
both in vitro and in ex vivo model. Pre-treatment of the iso-
lated rat heart with the specific STAT3 inhibitor, Stattic, 
supports the idea that STAT3 is crucial for EV-mediated pro-
tection. Moreover, in these EV silencing of dual-specificity 
phosphatase 6, a member of the MAPK phosphatase family, 
prevented STAT3 phosphorylation and cardioprotection in 
the rat heart. EV collected from patients subjected to RIPreC 
were found non-protective. "Hyperconditioning" [227] has 
been proposed for explaining the loss of EV-RIPreC-medi-
ated cardio-protection in these ACS patients, already suffer-
ing from ischemic events.
Another interesting study [97] suggested that the pro-
tection provided by RIPerC may be mediated not only by 
STAT3 pathway activation, which occurs only hours after the 
ischemia, but also by a more immediate neuronal response 
in pigs. Indeed, during the coronary occlusion the authors 
observed an attenuated ST-segment elevation in the RIPerC 
group, which correlated with reduced IS and was related to 
neuronal stimuli rather than circulating factors. In addition, 
it was found that splenectomy abolished RIPreC cardiopro-
tection and the RIPreC-induced STAT3 phosphorylation in 
pigs and in rats [133]. Besides, in rats only, the vagal nerve 
seems to have a mandatory role in the transduction of RIP-
erC cardioprotection.
Despite the majority of the preclinical studies confirming 
a causal role of STAT3 in the protective mechanism of RIC, 
other players may intervene and species-specific differences 
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may have a relevant influence too. Indeed, clinical evidence 
demonstrated the involvement of STAT5 in humans. In 
patients undergoing coronary artery bypass grafting (CABG) 
surgery, RIPreC was able to lower the troponin I levels and 
protect the myocardium, but STAT5 was the only STAT 
protein whose phosphorylation was significantly increased 
after applying RIPreC [56, 80]. Accordingly, in STAT5 KO 
mice, it has been reported that the cardioprotective effects 
against myocardial IRI by RiPreC are abrogated [30]. In 
particular, in these hearts, STAT5 was found to be crucial 
for RIPreC-mediated IS reduction through the PI3K/AKT 
survival pathway and the anti-apoptotic cascade, thereby 
confirming the importance of RISK in rodents. Conversely, 
STAT3 was found activated/phosphorylated in STAT5 KO 
mice and was not further phosphorylated by RIPreC, reveal-
ing that when STAT5 is deleted, STAT3 is phosphorylated, 
but this activation is not sufficient to reprogram RIPreC 
cardioprotection against IRI. Yet, in isolated mouse hearts 
with cardiomyocyte STAT3 deletion, STAT5 significantly 
increased following ischemic challenging [59]. However, in 
this study, the authors analyzed the cardiac function only and 
found that the STAT5 activation by IPrec in this STAT3 KO 
model is insufficient to rescue the cardiac function. From 
these two studies [30, 59] we can speculate that STAT3 is 
more implicated in cardiac function, whereas STAT5 is fun-
damental against IRI in rodents.
Clinical trials demonstrated the effectiveness of RIPreC 
in attenuating cardiac IRI and improving the short-term 
prognosis. In the work of Wu et al. [230], the induction of 
RIPreC in children with a severe congenital cardiac dis-
ease (tetralogy of Fallot) prior to cardiopulmonary bypass 
surgery, was able to reduce the length of intensive care 
unit stay, as well as postoperative Troponin I and Creati-
nine Kinase-MB levels. Interestingly, in the RIPreC group, 
they observed higher expression of cardiac Hif-1a, p-Akt, 
p-STAT3 in Y705, p-STAT5, p-NOS and less mitochondrial 
swelling compared to the control group.
In other human studies, the involvement of STATs was 
questioned. For instance, in patients with coronary artery 
disease who underwent CABG, RIPreC applied before sur-
gery was protective, as demonstrated by the lower Troponin 
I level [99]. Mitochondria isolated immediately after RIPreC 
showed increased ADP-stimulated complex I respiration, 
ATP production and  Ca2+ retention capacity, as well as 
reduced ROS production; the contractile function of atrial 
trabeculae dissected before surgery and subjected to HR pro-
tocol, was significantly improved by a RIPreC maneuver. 
Despite this, the expression and phosphorylation of proteins 
including STAT3 were not different between the RIPreC 
group and the control group. However, in this study, protein 
phosphorylation was analyzed in human atrial trabeculae 
after in vitro HR at only 1-timepoint; therefore, it is possible 
that changes in protein phosphorylation were missed.
In summary, although a number of experimental studies 
relating to the parallels between STAT3 and STAT5 exist, 
to better clarify the role of these two proteins in human 
myocardial IRI more studies are needed. From the existing 
studies on humans [18, 56, 80, 230] and on animals [30, 
59, 79], it appears that their roles in cardioprotection are 
largely species-specific. In some species/conditions STAT5 
can replace STAT3 in a sort of Yin/Yang relationship, in oth-
ers STAT5 appears as part of a completely different pathway.
Yet, some clinical studies [139, 152, 172] do not support 
the cardioprotective potential of RIPreC and this may be 
due to different factors, such as comorbidities of the patients 
as well as the choice of anesthetic during surgery (See also 
below “Effects of common risk factors and confounders on 
STAT3 cardioprotection”).
STAT3 in hypothermic conditioning
Hypothermia is known to preserve cardiac function and 
prevent mitochondrial damage upon cardiac IRI [163]. It is 
currently used in clinics to improve survival in post cardiac 
arrest settings [161]. STAT3 seems to be involved in the 
mechanism of protection underlying the hypothermic con-
ditioning [88]. Huang et al. [88] studied the mitochondria 
of rat hearts subjected to cardiac arrest and resuscitation 
with or without hypothermia (32 °C) and they observed less 
mitochondrial swelling and mPTPs opening in the hypo-
thermic group and amelioration of complex I/III activity of 
the ETC. Interestingly, the amount of Y705 phosphoryla-
tion and STAT3 expression in mitochondria was increased 
in hypothermic rats. The causal involvement of STAT3 was 
confirmed in vitro by the use of STAT3 inhibitor, which 
resulted in the abrogation of hypothermia-induced protection 
in H9c2 cells. Due to the relevance of this approach in the 
clinic, more studies on the mechanisms are needed.
STAT3 in pharmacological conditioning
Cardioprotection can be achieved thanks to administration 
of drugs and molecules before or after a coronary occlu-
sion, that are, respectively, pharmacological pre- and post-
conditioning, which can be induced either with exogenous 
or endogenous agents. Even low doses of TNFα, adminis-
tered as preconditioning or postconditioning agent, confer 
cardioprotection by modulating ROS production and inac-
tivating pro-apoptotic proteins, such as Bad [43, 116, 118]. 
Indeed, ROS may trigger TNFα-induced cardioprotection 
and their scavenging inhibits STAT3 phosphorylation [116, 
147]. There is evidence that JAK-STAT3 activation may 
be obtained by several other factors, such as bradykinin, 
opioids, ethanolamine, melatonin, resveratrol, erythropoi-
etin, cannabinoid agonists, insulin and prostaglandins (for 
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reviews see [71, 114, 115]). In addition, a link between HDL 
and STAT3 has been described [64].
Recently, as shown in rat hearts subjected to LAD liga-
tion, morphine preconditioning induced an increase in 
pY705 STAT3 and phosphorylated JAK2 and a reduction in 
IS [45]. Upon STAT3 inhibition with Stattic, these effects 
are lost, but using cyclosporine A, the protection is restored, 
suggesting that the positive effect of morphine relies on the 
inhibition of mPTPs that occurs downstream of STAT3 acti-
vation. Another study [62] about morphine conditioning on 
LAD-ligated rat hearts, highlights that morphine-induced 
pY705 STAT3 and phosphorylated JAK2 are fundamental in 
the crosstalk with RISK pathway, which in turn leads to the 
regulation of GSK-3β and confers cardioprotection. Indeed, 
Akt and GSK-3β phosphorylations are abrogated in presence 
of AG490, the inhibitor of JAK2/STAT3, and at the same 
time, STAT3 phosphorylation was abolished in the presence 
of the Akt inhibitor, wortmannin. The same crosstalk was 
observed by Shravah et al. [187] on H9c2 cells treated with 
propofol, an intravenous anesthetic exerting anti-apoptotic 
effects on cardiomyocytes. Propofol treatment induced phos-
phorylation of STAT3 in Y705 and S727; both of them were 
detected for up to 30 min, while at 6 h only Y705 phos-
phorylation was sustained. This finding correlates with the 
observation of nuclear translocation of STAT3 after 4 h of 
propofol treatment.
Evidence about STAT3 in mediating cardioprotection via 
the regulation of mitochondrial function is also provided by 
the work of Lemoine et al. [125]. They demonstrated that the 
administration of atorvastatin at early reperfusion prevents 
mPTPs opening and that this is dependent on STAT3 and 
TNF-alpha signaling in human atrial trabeculae model of 
H/R injury. In particular, in human atrial trabeculae exposed 
to H/R, atorvastatin ameliorated the contractile force in com-
parison with H/R control and increased Y705 STAT3 and 
JAK2 phosphorylation. Atorvastatin lost its cardioprotec-
tive effect in presence of TNFα and STAT3 inhibitors, while 
the addition of cyclosporine A (mPTPs opening inhibitor) 
restored the protection. This indicates an involvement of the 
SAFE pathway in the protection by atorvastatin and places 
the inhibition of mPTPs opening downstream of the activa-
tion of TNFα, JAK2, and STAT3.
Sodium–glucose cotransporter-2 inhibitors (SGLT2) are 
emerging as a class of anti-diabetic compounds exerting 
unexpected beneficial cardiovascular effects [6]. Among 
the SGLT2 inhibitors, different mechanisms of cardiopro-
tection have been reported. For example, empagliflozin 
reduces IS by increasing STAT3 phosphorylation at early 
reperfusion in in vivo hearts of mouse fed weed western diet 
to induce diabetes [7]. Moreover, in healthy mice, chronic, 
but not acute, empagliflozin administration reduces IS via 
the STAT3 pathway [160]. Yet, another SGLT2 compound, 
dapagliflozin, attenuates cardiac fibrosis by regulating the 
macrophage polarization via STAT3 signaling in infarcted 
rat hearts [123]. Distinct mechanisms of cardioprotection 
could be speculated among the various SGT2 inhibitors.
Many endogenous compounds used in pharmacologi-
cal conditioning induce STAT3 signaling. For example, the 
obesity-related adipokine leptin protects against IRI in vari-
ous tissues including gut, kidney, brain and heart in which 
leptin activates both RISK and SAFE pathways [193]. Actu-
ally, the cardiac leptin signaling has been demonstrated to 
be fundamental to the cardiac structure and function after 
MI, by attenuating hypertrophy and metalloproteinase activ-
ity, reducing cardiomyocytes apoptosis and inflammation, 
maintaining the left ventricle contractility and preventing 
left ventricular dilation [148, 149]. In particular, Mcgaffin 
et al. [149] performed LAD ligation on cardiomyocyte-spe-
cific leptin-deficient mice and they found reduced cardiac 
function associated with the loss of STAT3 signaling and 
STAT3-responsive gene transcription. Smith et al. [193], 
using isolated rat hearts treated with leptin at the begin-
ning of reperfusion, found a decrease in IS as well as early 
(2,5 min) STAT3 Y705 phosphorylation and subsequent 
(15 min) Akt phosphorylation. The addition of AG490 
caused the loss of leptin-induced protection but did not affect 
Akt levels. In vitro, they observed that leptin postcondition-
ing reduced mPTPs opening; this effect was abrogated in 
presence of AG490, indicating that STAT3 may be involved 
in mitochondrial regulation.
Another hormone, ghrelin, has been tested in the context 
of cardioprotection. Ghrelin is a 28 amino acid peptide ini-
tially isolated from the stomach, whose acylation is essential 
for binding to growth hormone (GH)-secretagogues-recep-
tor type 1a and its endocrine functions. Although lacking 
GHS-R binding, unacylated ghrelin shares several effects 
with acylated ghrelin. Ghrelin exerts different activities on 
the cardiovascular system, such as modulation of cardiac 
contractility, inhibition of cardiac and endothelial cells 
apoptosis and improvement of left ventricular function in 
IR heart [168]. Treatment of rats with ghrelin for 3 weeks, 
after induction of MI, improved LV contraction, decreased 
expression of pro-apoptotic proteins, determined myocardial 
suppressor of cytokine signaling 3 (SOCS3) expression (an 
inhibitor of JAK2/STAT3 signaling) and STAT1 phospho-
rylation, improved antioxidant activity and increased JAK2 
phosphorylation and STAT3 phosphorylation in both Y705 
and S727 in a rat model of MI with LAD ligation [47]. 
According to these results, the protective effect of ghrelin 
may be mediated by the inhibition of JAK1/STAT1 signal-
ing, which leads to pro-apoptotic effects, and by the inhibi-
tion of SOCS3. Using cardiac-specific SOCS3 KO mice, it 
has been shown that SOCS3 is key factor that exacerbates 
the myocardial IRI development [155].
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In ex vivo (isolated rat hearts) model and in vitro (iso-
lated mouse cardiomyocytes) model of IR, Fuglesteg et al. 
[53] demonstrated that insulin induces cardioprotection at 
reperfusion, by activating STAT3. Again, the inhibition of 
STAT3 through AG490, negatively affected the activation 
of Akt, suggesting a crosstalk between these two mediators.
We mentioned above the importance of S1P in STAT3 
activation. Actually, S1P is a proinflammatory mediator of 
allergic diseases and exerts its functions through five specific 
cell surface receptors (S1PR1-5) [105, 141, 216]. However, 
S1P is also a potent protectant against IRI [179, 214]. The 
S1P cardioprotection is mediated by interaction with types 
1, 2 and/or 3 S1PRs leading to the activation of RISK and/
or SAFE pathways [37, 150]. Specifically, S1P treatment at 
early reperfusion protected isolated mice hearts subjected to 
IR by activating both RISK and SAFE pathways [197]. In 
this model, the decrease in IS was abolished both with the 
use of AG490 and  STAT3−/− mice. Interestingly, they found 
a peculiar kinetic of STAT3 S727 phosphorylation in the 
different cell compartments: an increase in phosphorylation 
was found both in the nucleus and in the mitochondrial frac-
tion at 7 min post-reperfusion, while it persisted at 15 min 
post-reperfusion only in the nucleus: STAT3 translocation 
to mitochondria may be related to its cardioprotective effect.
In conclusion, exogenous and endogenous compounds 
may induce pharmacological conditioning involving either 
RISK and/or SAFE pathways. Undoubtedly, further research 
is needed to delineate the main mechanisms involved in 
cardioprotection induced by these agents. Furthermore, the 
elucidation of the possible protective mechanisms of these 
factors on myocardium with or without comorbidities could 
increase the probability of success in terms of translating 
cardioprotection in the clinical setting for a real benefit of 
the patient. Since STAT3 is involved in a wide range of 
patho-physiological cardiac conditions, pharmacological 
activation or inhibition of STAT3 may be represent a thera-
peutic strategy to treat them.
Some more considerations on mitochondrial 
STAT3 in IRI and cardioprotection
As seen above, STAT3 is a major member of the well-known 
cardioprotective SAFE pathway that leads to the activation 
of several pro-survival signals contributing to protect cells 
against IRI. There is a number of studies [23, 53, 83, 147, 
157, 194] evidencing the essential role of STAT3 in cardio-
protection against IRI, also through the use of STAT3 KO 
and pharmacological STAT3 inhibition. The KO of STAT3 
and the inhibitors AG490 and Stattic are commonly used 
techniques to study the role of STAT3; these methods block 
all the functions of STAT3, without discriminating between 
transcriptional and mitochondrial function. Several studies 
showed that STAT3 is phosphorylated and activated in dif-
ferent timepoints of IR episode, but only few works have 
been done to distinguish and characterize the S727 and 
Y705 phosphorylation and their effects on STAT3 localiza-
tion and function. A possible reason for this lack of insight 
can be due to the complexity of the model required to study 
separately STAT3 as a transcription factor and STAT3 as 
a mitochondrial effector, since no well-defined mechanism 
to distinguish them has been found yet. The different sites 
of phosphorylation, S727, and Y705, may represent a way 
to identify different activities of STAT3, but more stud-
ies should be done to verify if phosphorylation on S727 
is specifically and univocally required for the mitochon-
drial action. Until now the S727 site seems to be important 
for some of the mitochondrial functions of STAT3, but it 
cannot be considered yet a specific marker to define mito-
chondrial STAT3. One interesting method that has been 
adopted by some research groups that wanted to focus only 
on mitochondrial STAT3 is the creation of MLS-STAT3, 
which is obtained by fusing the sequence of STAT3 with 
the mitochondrial targeting sequence of the subunit VIII of 
cytochrome c. The main disadvantage of this technique is 
that it forces the expression of a non-physiological mito-
chondria-targeted STAT3, and as such it does not allow 
to study of what happens physiologically in myocardium. 
Heusch et al. [79] observed that the reduction in IS caused 
by IPostC in pig hearts was accompanied by a better mito-
chondrial function, with preservation of complex I and better 
 Ca2+ retention capacity; interestingly, in mitochondria from 
post conditioned pig heart they found an increased phospho-
rylation of mitochondrial STAT3 at the Y705 site. Among 
the few researchers that investigated the role of mitochon-
drial STAT3 in the IRI model, Szczepanek et al. [205] used 
transgenic MLS-STAT3 mice; in MLS-STAT3 hearts they 
found a better response to IR in term of IS and contractile 
recovery, as well as reduction of ROS after reperfusion, in 
comparison with WT hearts [204, 206]. The same group 
studied how mitochondrial function in particular complex 
I respiration, was improved by STAT3 overexpression in 
mitochondria, suggesting that the protective mechanism 
mediated by STAT3 is independent of its activity as a tran-
scription factor. Wang et al. [220] have demonstrated that 
the zinc transporter Zip2 regulates mitochondrial respira-
tion via STAT3 phosphorylation during IR. In particular, 
in  Zip2−/− mice undergoing an in vivo LAD ligation, mito-
chondrial respiratory rates and oxidative phosphorylation 
are decreased together to the levels of S727-phosphorylated 
STAT3. The restoration of mitochondrial function occurred 
only upon the reintroduction of STAT3 expression, while 
STAT3 dominant negative mutant (STAT3 S727A) inhibited 
mitochondrial respiratory function, suggesting the impor-
tance of the S727 site for mitochondrial regulation.
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In cardiomyocyte STAT3 KO mice, Hilfiker-Kleiner 
et al. [83] observed increased mRNA levels of the pro-
autophagy/pro-apoptotic protein BNIP3 24 h after reperfu-
sion, while mRNA levels of the prosurvival gene HSP70 
were decreased. They described greater apoptosis and IS 
with impaired fractional shortening after 7 days. However, 
no changes were observed in VEGF and in the anti-oxidant 
protein SOD2.
Yet, STAT3 signaling, other than regulating many 
responses in cardiomyocytes, is also active in the endothe-
lial cells, where it contributes to anti-inflammatory and 
anti-apoptotic response [251], angiotensin II-induced fibro-
sis [86], oxidative stress modulation [7], and vasodilation 
[224]. According to this, endothelial STAT3 may have an 
important role in the protection versus IRI; for example, in 
mouse model of IR, the ablation of endothelial STAT3 led 
to a decrease of cardiac function supported by increased 
inflammation and worsening of capillary integrity [221]. 
Other authors demonstrated that in hypoxic human coronary 
artery endothelial cells, the treatment with statin rosuvasta-
tin improved cell survival through the JAK/STAT3 pathway 
[218].
Effects of common risk factors 
and confounders on STAT3 cardioprotection
Obviously, in AMI patients, it is possible to apply treat-
ment only after the ischemia at early reperfusion, since the 
ischemic event cannot be predicted. As seen, pharmacologi-
cal postconditioning at the early reperfusion phase promotes 
pro-survival and antioxidant mechanisms in the damaged 
cells and the treatment at late reperfusion appears to be less 
efficient [58]. Therefore, the studies about pharmacological 
postconditioning are the most relevant to clinical reality. As 
seen, STAT3 seems to have a protective role in various mod-
els of cardiac IR, even if different results about the timing 
and site of activation are present. Nevertheless, the results 
obtained in pre-clinical studies often do not correspond to 
the findings in clinical studies, suggesting that the species-
specific differences in the responsiveness to treatment are 
strongly relevant. Yet, multiple factors including comor-
bidities and/or co-medications may influence the molecular 
environment in cardiac and non-cardiac tissues, determining 
the outcome in humans in the responses to RIC maneuvers 
[50, 98].
A known confounder of cardioprotection by RIC is the 
anesthesia. In this respect, STAT5 function may be relevant. 
As mentioned, it has been proposed that the SAFE path-
way plays a more important role in larger mammals, where 
STAT5 is also important, making it particularly interesting 
from a translational viewpoint [70, 79, 189, 190]. Indeed, 
STAT5 phosphorylation is not only associated with, but 
causally involved in cardioprotection as suggested by the 
clinical study of Kottenberg et al. [101]. In this study propo-
fol interfered with STAT5 activation and consequently with 
RIPreC-mediated protection, suggesting an association 
between a lack of RIPreC effect and the lack of STAT5 acti-
vation. Nevertheless, RIC decreased troponin release and 
increased STAT5 phosphorylation in patients undergoing 
cardiac surgery under isoflurane [80]. Augmented STAT5 
phosphorylation in the left ventricle was also observed dur-
ing cardioprotection under sevoflurane anesthesia [230]. The 
difference may be due to intravenous anesthesia (propofol) 
or volatile anesthesia, as suggested by the network meta‐
analysis of randomized trials, which confirmed the interfer-
ence of intravenous anesthesia with RIC in reducing post‐
operative mortality [242].
Actually, a multitude of risk factors influences the onset 
and prognosis of ischemic heart disease, altering endoge-
nous cardiac signaling and possibly interfering with cardio-
protective strategies, including IPreC and IPostC [50, 98]. 
Since confounding factors such as age, sex, diabetes, and 
hypertension/hypertrophy may alter the benefits provided 
by the activation of the RISK and SAFE pathway, here we 
consider possible effects that these unfavorable factors may 
have on cardiac STAT3. Again, the majority of the evidence 
about confounder’s influence refers to STAT3 in the SAFE 
pathway, but a few studies can be linked specifically to the 
mitochondrial function of STAT3. Here, we consider some 
of these confounders and analyze the variations occurring 
on phosphorylation of S727 STAT3, the putative key step 
for STAT3 entry within mitochondria.
Aging
Effects on the extent of IRI
Aging enhances the extent of IRI in unprotected myocar-
dium due to age-induced defects in mitochondrial function 
as shown by Lesnefsky and Hoppel group [126, 127]. This 
may be related to STAT3 inhibition. Indeed, in aging rat 
heart lower phosphorylation of total STAT3 in comparison 
with younger animals has been observed [29]. Furthermore, 
Wegrzyn et al. [225] demonstrated that in mice STAT3 null 
hearts, the activities of complex I and II are decreased, lead-
ing to a reduction in the oxidative phosphorylation system 
(OXPHOS) efficacy.
Effects on cardioprotection
Aging is known to reduce the protection associated with 
ischemic conditioning, and a possible explanation may be 
the impairment of mitochondrial function and TNF-stimu-
lated signaling, such as the SAFE pathway [18, 20, 126]. In 
aged rodents IPostC applied at reperfusion resulted in less 
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efficiency in reducing IS in comparison with younger mice, 
and the increased IS was associated with reduced phos-
phorylation of S727 STAT3 [18]. In particular, in young 
mice (3 months) both 3 cycles of 10 s of ischemia/10 s of 
reperfusion (3 × 10 s) and 5 cycles of 5 s of ischemia/5 s 
of reperfusion (5 × 5 s) reduced IS, whereas in aged mice 
(> 13 months), only 5 × 5 s was effective in reducing the 
infarct area. In young mice, 3 × 10 s IPostC increased the 
phosphorylation of STAT3 in S727 at 10 min of reperfusion, 
whereas in aged mice hearts, phosphorylated STAT3 was 
reduced compared with young mice hearts. Other groups 
demonstrated that in the heart from old mice there is a 
lower expression of total STAT3. For example, Boengler 
et al. [20] reported a reduced STAT3 protein level in mito-
chondria isolated from cardiac tissue of aged mice compared 
to younger mice. Furthermore, in this study Boengler et al. 
[20] suggested the potential clinical relevance of STAT3 by 
highlighting that a reduced level of mitochondrial STAT3 in 
elderly hearts may be important for the loss of cardioprotec-
tion. Taken together, these studies highlighted the reduced 
STAT3 level in aged hearts with higher susceptibility to IR 
challenging and subsequent loss of cardioprotection.
Diabetes
Effects on the extent of IRI
In addition to harmful consequences of diabetes on the car-
diovascular system, such as cardiopathy and vasculopathy, 
diabetes increases specifically the risk to develop ischemic 
heart disease [34, 167]. Interestingly, diabetes seems to alter 
cardiac STAT3 signaling, lowering its activation at the S727 
site in both in vivo and in vitro models [217], even if in 
some other cases, increased activation of canonical STAT3 
was observed in diabetic animals [203]. Of note, STAT3 
is known to protect the heart from oxidative stress ant it is 
able to preserve the myocardium in postpartum cardiomyo-
pathy in female mice [84]. Indeed, a specific cardiac dele-
tion of STAT3 in KO females leads to this disease [84]. The 
involvement of STAT3 in either the activation of diabetic 
or antidiabetic mechanisms in the development of diabetic 
and postpartum cardiomyopathy has been summarized in 
a recent review [66]. Despite not all evidence being coher-
ent, diabetes contributes to worsening IRI, most likely 
through induction of oxidative stress and consequent loss 
of cardioprotective strategies efficacy [165]. For example, 
reduced STAT3 S727 phosphorylation in diabetic rats has 
been linked to increased susceptibility to IRI, resulting in 
increased IS [131, 217].
Effects on cardioprotection
Lei et al. [124] demonstrated that pharmacological precondi-
tioning with Remifentanil in rats increased phosphorylation 
of STAT3 at Y705 and reduced IS. These protective effects 
were abrogated in diabetic rats, in which STAT3 failed to 
be phosphorylated both at Y705 and S727 [124]. The study 
of Liu et al. [136] investigated the influence of diabetes on 
RIPreC maneuver on rats. In particular, in diabetic rats sub-
jected to liver RIPreC, IS and apoptosis level were reduced 
to the same extent as in non-diabetic rats. Interestingly, the 
cardioprotection of liver RIPreC in diabetic rats appeared to 
rely on GSK-3β/STAT5 signaling, since STAT5 activation 
and not STAT3 was detected in these hearts. Therefore, not 
all the evidence converges towards a single conclusion, but 
this can be due to the fact that diabetes can modulate the 
cardiac environment towards a less or more protective one 
in the different phases of its pathophysiology [167].
Cardiac hypertrophy
Several studies highlighted that the inhibition of STAT3 
induces downregulation of synthesis of collagen and subse-
quently regression of hypertrophy. Moreover, overexpres-
sion of STAT3 in murine cardiomyocytes leads to cardiac 
hypertrophy by increasing expression of hypertrophic genes, 
such as atrial natriuretic factor (ANF) [66, 106]. Regarding 
STAT3's role in mitochondrial regulation of cardiac hyper-
trophy, it protects mitochondria indirectly via upregulation 
of the anti-apoptotic proteins, such as Bcl2. In addition, 
STAT3 preserves mitochondrial integrity and inhibits ROS 
generation via its interaction with CypD and inhibition of 
the opening of the mPTPs [78, 87, 151]. Finally, Chen et al. 
[31] investigated whether angiotensin II-induced cardiomyo-
cyte hypertrophy is affected by STAT3-mediated inhibition 
of cellular autophagy on H9c2. They reported that STAT3 
modulates autophagy to balance the transcriptional hyper-
trophic response to angiotensin II stimulation.
Under stressful conditions, high levels of catecholamine 
are associated with several types of cardiac dysfunction, 
such as arrhythmias, coronary spasm,  Ca2+ abnormalities 
in sarcolemma and sarcoplasmic reticulum, deficiency in 
mitochondrial energy production and myocardial cell dam-
age, as well as cardiac hypertrophy [2, 90, 93]. Several fac-
tors have been proposed as promoters of hypertrophy [208]; 
among them, STAT3 was examined by Jeong et al. [93] in an 
in vitro model of catecholamine-induced hypertrophy. In this 
model they observed an impaired oxidative phosphoryla-
tion in mitochondria, as demonstrated by the downregulation 
of mitochondrial complexes II and III. In particular, they 
attributed a regulatory role to STAT3 phosphorylation at 
both Y705 and S727 sites in these hypertrophic H9c2 cells 
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exposed to catecholamines. While the expression and activa-
tion of pY705-STAT3 in the nucleus were increased lead-
ing to the transactivation of hypertrophic responsible genes, 
such as ANF and c-fos, the pS727-STAT3 phosphorylation 
in mitochondria was attenuated. Moreover, the oxidative 
phosphorylation system of mitochondria was significantly 
downregulated, likely through the reduction of pS727-
STAT3 activation.
Moreover, Stapel et al. [199] emphasize the critical impli-
cation of STAT3 in the sensitivity of β-adrenergic receptor 
(BAR) toxicity. They observed reprogrammed cardiomyo-
cyte oxygen metabolism upon β-adrenergic stimulation in 
STAT3 KO mice, in particular an increased ADP/ATP ratio 
and lower  O2 consumption.
In an effort to identify the potential involvement of 
STAT3 in β-adrenergic signaling Zhang et al. [246] studied 
BAR-mediated STAT3 activation, using conditional STAT3 
KO (STAT3cKO) mice hearts. STAT3 should be involved in 
the regulation of BAR signaling via cAMP. In particular, in 
STAT3cKO hearts upon BAR stimulation cAMP level were 
downregulated and this was associated with lower left ven-
tricular contractile and relaxation properties. This evidence 
was supported by the results obtained in the in vitro car-
diomyocyte STAT3cKO model, where they found reduced 
anti-apoptotic proteins, indicating the activation of apoptotic 
processes.
Overall, these experimental studies suggest that a modu-
lation of STAT3 plays a central role in the development of 
hypertrophy and may represent a new therapeutic strategy to 
treat cardiac hypertrophy. Whether these effects contribute 
to IRI exacerbation and loss of cardioprotection remains to 
be ascertained.
Effects on the extent of IRI
Several cardiovascular pathologies as well as hypertension 
can cause maladaptive hypertrophy of cardiac myocytes 
in response to an increased workload. When hypertro-
phy develops, IRI are exacerbated and cardioprotection is 
compromised; for Review see [165]. Moreover, Enomoto 
et al. [48] demonstrated that cardiac-specific ablation of the 
STAT3 gene exacerbated post-infarct cardiac remodeling. 
In particular, in STAT3 null mice, reduced capillary den-
sity was detected compared to control mice after myocardial 
infarction, suggesting that cardiac specific ablation of the 
STAT3 gene leads to severe hypertrophy without coordina-
tion with capillary growth. Overall, STAT3 downregulation 
by hypertrophic pathological conditions can exacerbates IRI, 
and STAT3 intrinsic activity is required for the prevention 
of maladaptive cardiac remodeling in the subacute phase of 
myocardial infarction.
Effects on cardioprotection
On the other hand, STAT3 downregulation by hypertrophic 
pathological conditions can also lead to the loss of efficacy 
of cardioprotective maneuvers, such as RIC [165]. In a clini-
cal study, Sloth et al. [192] observed in 139 patients with 
STEMI and left ventricular hypertrophy that the RIPreC 
effect tended to be attenuated, even if no statistic differ-
ences were reached neither for patients with hypertrophy nor 
with hypertension. In the work of Song et al. [198], RIPreC 
was ineffective in inducing the activation of cardioprotec-
tive pathways (RISK and SAFE) when applied before aortic 
valve replacement in patients suffering from aortic stenosis, 
who are characterized by concentric left ventricular hyper-
trophy. CK-MB and troponin I levels were not affected by 
the RIPreC, as well as no changes in RISK pathway elements 
nor in STAT3 phosphorylation were detected. STAT5 phos-
phorylation was decreased in the RIPreC group, and caspase 
3 was upregulated, suggesting that some cellular damage has 
occurred. These results lead to the conclusion that the pres-
ence of a hypertrophic phenotype influences the outcome of 
RIPreC maneuver, but the reason remains unclear. A pos-
sible explanation for lack of activation of the RISK pathway 
can be that in myocardium with chronic hypertrophy, a per-
sistent activation of Akt exists [145], which might be linked 
to a feedback inhibition of upstream RISK pathway.
Overall, in several cardiac responses observed in hyper-
trophic hearts, such as stress adaptation, pathological remod-
eling, heart failure, IRI and cardioprotection modifications, 
STAT3 shows a fundamental function as a critical transcrip-
tion factor and/or a modulator of mitochondrial function.
Conclusion
Overall, in this review, we highlight the role of STAT3 as a 
protein with non-genomic functions. Initially, the research 
focused on the genomic functions of STAT3, as a transcrip-
tion factor, but then it became clear that it has a fundamental 
role in the mitochondria and in the non-genomic network 
[e.g., 20, 210, 225], opening the horizon towards the under-
standing of the pro-survival functions of this protein.
In cardioprotection scenario, STAT3, by regulating mito-
chondrial  Ca2+ and ROS homeostasis and preventing mPTPs 
opening, contributes to the recovery of mitochondrial func-
tion following IR episode, which is a fundamental prereq-
uisite in the mechanism of efficient cardiac conditioning.
Although the most recent data suggest that optimal car-
dioprotection can be reached with the combination of addi-
tive or synergistic multitarget therapies [39], understanding 
how to preserve the ΔΨm and maintain the proton motive 
force by preserving the normal function of the F1F0-ATPase 
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pump would undoubtedly result in an improvement in the 
response to IR. The available data on STAT3 in mitochon-
dria and its influence on mitochondrial function represent a 
basis for further studies addressing the exact contribution of 
the role of mitochondrial proteins in cardioprotection.
Here we have discussed some recent studies that highlight 
the key role of STAT3 in cardioprotection, which, together 
with other regulatory (e.g., STAT5) and pathways, plays a 
central role also in humans and in experimental models rel-
evant for translation from bench research to clinic [e.g., 79, 
80, 98, 100, 101, 191].
We hope that the results reported in this review will 
encourage more and more researchers to deepen their studies 
and clarify the remaining doubts about STAT3 pro-survival 
role in the cardiovascular field. In particular, the function 
exerted on the ETC to maintain its efficiency and prevent 
ROS formation represents an excellent starting point to jus-
tify the interest in understanding the mechanisms underlying 
this role of STAT3 within mitochondria.
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